{
    "id": "yago_7859_0",
    "rank": 44,
    "data": {
        "url": "https://directory.uthscsa.edu/academics/profile/mesar",
        "read_more_link": "",
        "language": "en",
        "title": "Mesa, Ruben A. MD",
        "top_image": "https://directory.uthscsa.edu/sites/profiles/files/styles/facebook/public/acad-images/rubenmesa.jpg?itok=rC_iPuCq",
        "meta_img": "https://directory.uthscsa.edu/sites/profiles/files/styles/facebook/public/acad-images/rubenmesa.jpg?itok=rC_iPuCq",
        "images": [
            "https://directory.uthscsa.edu/sites/profiles/files/styles/acad_profile/public/acad-images/rubenmesa.jpg?itok=zeR0MU94",
            "https://directory.uthscsa.edu/sites/profiles/files/addtl-images/home_map_image.gif"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2020-04-02T09:14:53-05:00",
        "summary": "",
        "meta_description": "Dr. Ruben Mesa is the director of UT Health San Antonio MD Anderson Cancer Center, one of only four National Cancer Institute-designated cancer centers in Texas. For almost 30 years the cancer center has had a deep focus on providing world-class cancer care, advancing cancer research and educating the next generation of cancer care scientists and care providers. Dr. Mesa’s practice builds on his role as an international expert on myeloproliferative neoplasms (MPNs), a group of bone marrow disorders that often lead to leukemia. He has been involved in MPN research for more than 20 years. He led the development of National Comprehensive Cancer Network’s panel guidelines, the first U.S. guidelines on the diagnosis and treatment of myelofibrosis, polycythemia vera and essential thrombocythemia. Dr. Mesa has been the principal investigator or co-principal investigator of more than 70 clinical trials. He co-led the research team leading to the FDA’s approval of ruxolitinib for polycythemia vera and myelofibrosis. He is currently leading the investigation of several other drugs for these types of cancers. Dr. Mesa was elected to sit on the National Board of Directors for the Leukemia and Lymphoma Society and sits on the board of the MPN Education Foundation. After earning degrees in nuclear engineering and physiology, with minors in radiation biophysics and bioengineering, from the University of Illinois at Urbana-Champaign, Dr. Mesa received his medical degree from the Mayo Graduate School at the Mayo Clinic College of Medicine in Rochester, Minnesota. He completed his residency in internal medicine and his fellowship in hematology/medical oncology at Mayo. He is a fellow of the American College of Physicians and is certified by the American Board of Internal Medicine in hematology and medical oncology.",
        "meta_lang": "en",
        "meta_favicon": "https://directory.uthscsa.edu/misc/favicon.ico",
        "meta_site_name": "Profiles",
        "canonical_link": "https://directory.uthscsa.edu/academics/profile/mesar",
        "text": "Abstract\n\nMascarenhas J, Virtgaym E, Stal M, Blacklock H, Gerds AT, Mesa R, Ganly P, Snyder D, Tabbara I, Tremblay D, Moshier E. Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study. doi: 10.1007/s00277-018-3309-6. Epub 2018 Apr 3. PMID:29616317; 2018 Aug. (Ann Hematol; vol. 97, no. 8). Leslie Padmos, Matthew Buras, Heidi Kosiorek, Robyn Scherber, Emily Knight, Andrea Cuc, Cynthia Stonnington, Amylou Dueck, Yonas Geda, Ruben Mesa. Myeloproliferative Neoplasms and Acceptance and Commitment Therapy: An Ongoing Feasibility Study Aimed at Symptom Mitigation and Quality of Life; 2018 Jun. (EHA Learning Center). Robyn Marie Scherber, Lindsey J. Whyte, Michelle Woehrle, Amylou C. Dueck, Srdan Verstovsek, Claire Harrison, Ruben A. Mesa. Creation and validation of the \"myMPN\" prospective patient registry of myeloproliferative neoplasm patients; 2018 Jun. Ruben A. Mesa, Giovanni Barosi, Claire N. Harrison, Jean-Jacques Kiladjian, Robert Peter Gale, Abderrahmane Laadem, Torsten Gerike, Peter G. Linde, Matthew L. Sherman, Joseph Pariseau, Srdan Verstovsek. A phase 2, multicenter, open-label study of the safety and efficacy of luspatercept in subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia with or without RBC transfusion dependence; 2018 Jun. Claire Harrison, Mary Frances McMullin, Anesh Panchal, Christina Yap, Sonia Fox, Rebecca Bishop, Natalia Curto-Garcia, Jason Coppell, John Laurie, Mamta Garg, Joanne Ewing, Steven Knapper, Josephine Crowe, Zor Maung, Anna Godfrey, Nicki Panoskaltsis, Robyn Scherber, Holly Geyer, Amylou Dueck, Ruben Mesa, Adam Mead. Ruxolitinib Compared With Best Available Therapy For Polycythaemia Vera Patients Resistant or Intolerant to Hydroxycarbamide in MAJIC-An Investigator-LED Randomised Trial; 2018 Jun. Holly Geyer, Robyn Scherber, Jeanne Palmer, Amylou Dueck, Marlene Girardo, Leslie Padmos, Ruben Mesa. Relationship Between MPN Pain and Emotional Health: An Analysis by the MPN Quality of Life International Study Group; 2018 Jun. Jennifer Huberty, Ryan Eckert, Linda Larkey, Krisstina Gowin, Jules Mitchell, Ruben Mesa. Qualitative Study Investigating The Perceptions of Myeloproliferative Neoplasm Patients Participating in an Online Yoga Intervention; 2018 Jun. Diaz AE, Mesa RA. Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia. doi: 10.2217/fon20170494. Epub 2017 Dec 13. PMID: 29235894; 2018 Apr. (Future Oncol; vol. 14, no. 9). Yu J, Parasuraman S, Paranagama D, Bai A, Naim A, Dubinski D, Mesa R. Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey. doi: 10.1186/s12885-018-4322-9. PMID:29653557; 2018 Apr. (BMC Cancer; vol. 18, no. 1). Jeanne Palmer, Heidi E. Kosiorek, Craig Zimmerman, Oleh Zagrijtschuk, John Camoriano and Ruben A. Mesa. Clinical Benefit of Ropeginterferon Alfa 2b (P1101) in Patients with Myelofibrosis; 2018 Jan. (Blood). Krisstina L. Gowin, Karen K. Ballen, Kwang Woo Ahn, Zhen-Huan Hu, Ying Liu, Lucia Masarova, Srdan Verstovsek, Maria Coakley, Tania Jain, Andrew Kuykendall, Rami Komrokji, Martha Wadleigh, Sarah Patches, Murat Arcasoy, Michael Green, Malathi Kandarpa, Moshe Talpaz, Haris Ali, Vikas Gupta, Rebecca Devlin, Laura C. Michaelis, Gabriela S. Hobbs, Brady Lee Stein, Ashley Pariser, Aaron T. Gerds, Kierstin Kuber, Raajit Rampal, Edwin P. Alyea III, Uday Popat, Ronald Sobecks, Bart L Scott, Ruben Mesa and Wael Saber. Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score; 2018 Jan. (Blood). John Mascarenhas, Heidi E. Kosiorek, Josef T. Prchal, Alessandro Rambaldi, Dmitriy Berenzon, Abdulraheem Yacoub, Claire N. Harrison, Mary Frances McMullin, Alessandro M. Vannucchi, Joanne Ewing, Casey L. O`Connell, Jean-Jacques Kiladjian, Adam J. Mead, Elliott F. Winton, David S. Leibowitz, Valerio De Stefano, Murat O. Arcasoy, Craig M. Kessler, Rosalind Catchatourian, Damiano Rondelli, Richard T. Silver, Andrea Bacigalupo, Arnon Nagler, Marina Kremyanskaya, Lonette Sandy, Mohamed E. Salama, Vesna Najfeld, Joseph Tripodi, Rona Singer Weinberg, Leah Price, Judith D Goldberg, Raajit K. Rampal, Ruben A. Mesa, Amylou C. Dueck and Ronald Hoffman. Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocyt; 2018 Jan. (Blood). Allison Gathany, Robyn M. Scherber, Marlene Girardo, Heidi E. Kosiorek, Amylou C. Dueck, Holly Geyer, Veena D. S. Fauble, Alessandro M. Vannucchi, Ana Kerguelen Fuentes, Christen Lykkegaard Andersen, Elisabeth Ejerblad, Gunnar Birgegard, Peter L. Johansson, Bjorn Andreasson, David M Ross, Federico Sackman, Jean-Loup Demory, Constantine S. Tam, Jan J. Michiels, Deepti Radia, Joanne Ewing, Frances Wadelin, Robert N. Lown, Mary Frances McMullin, Wunna Swe, Jonathan O. Cullis, Nigel Sargant, Paul Moreton, Catherine Cargo, Mallika Sekhar, Satareh Shekouhi and Ruben A. Mesa. Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial; 2018 Jan. (Blood). Ruben A. Mesa, Heidi E. Kosiorek, John Mascarenhas, Josef T. Prchal, Alessandro Rambaldi, Dmitriy Berenzon, Abdulraheem Yacoub, Claire N. Harrison, Mary Frances McMullin, Alessandro M. Vannucchi, Joanne Ewing, Casey L. O`Connell, Jean-Jacques Kiladjian, Adam J. Mead, Elliott F. Winton, David S. Leibowitz, Valerio De Stefano, Murat O. Arcasoy, Craig M. Kessler, Rosalind Catchatourian, Damiano Rondelli, Richard T. Silver, Andrea Bacigalupo, Arnon Nagler, Marina Kremyanskaya, Lonette Sandy, Mohamed E. Salama, Vesna Najfeld, Joseph Tripodi, Rona Singer Weinberg, Raajit K. Rampal, Ronald Hoffman and Amylou C. Dueck. Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III; 2018 Jan. (Blood). Jean-Jacques Kiladjian, Pierre Zachee, Masayuki Hino, Fabrizio Pane, Tamas Masszi, Claire N. Harrison, Ruben A. Mesa, Carole B. Miller, Francesco Passamonti, Simon Durrant, Martin Griesshammer, Keita Kirito, Carles Besses, Beatriz Moiraghi, Elisa Rumi, Vittorio Rosti, Igor W. Blau, Nathalie Francillard, Tuochuan Dong, Monika Wroclawska, Alessandro M. Vannucchi and Srdan Verstovsek. Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV); 2018 Jan. (Blood). Raajit K. Rampal, John Mascarenhas, Heidi E. Kosiorek, Rupali Bhave, Elizabeth O. Hexner, Eunice S. Wang, Aaron T. Gerds, Mark L Heaney, Camille N Abboud, Marina Kremyanskaya, Dmitriy Berenzon, Olatoyosi Odenike, Elizabeth Virtgaym, Lonette Sandy, Rona Singer Weinberg, Vesna Najfeld, Mohamed E. Salama, Ross L. Levine, Ruben A. Mesa, Amylou C. Dueck and Ronald Hoffman. Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial); 2018 Jan. (Blood). Onima Chowdhury, Jennifer O`Sullivan, Nikolas Barkas, Gemma Buck, Angela Hamblin, Ayalew Tefferi, Haifa Al-Ali, Giovanni Barosi, Timothy Devos, Heinz Gisslinger, Qian Jiang, Jean-Jacques Kiladjian, Ruben A. Mesa, Francesco Passamonti, Vincent Ribrag, Gary J. Schiller, Alessandro M. Vannucchi, Daobin Zhou, Mary Frances McMullin, David Reiser, Jim Zhong, Robert Peter Gale and Adam J. Mead. Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide; 2018 Jan. (Blood). Srdan Verstovsek, Robert P. Hasserjian, Olga Pozdnyakova, Ivo Veletic, Ruben A. Mesa, Lynda Foltz, John Mascarenhas, Ellen K. Ritchie, Jeanne Palmer, Richard T. Silver, Marina Kremyanskaya, Bernt van den Blink, Renu Gupta, Taghi Manshouri, C. Cameron Yin, Zeev E. Estrov and Jason R. Gotlib. PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study; 2018 Jan. (Blood). Stephen T Oh, Moshe Talpaz, Aaron T. Gerds, Vikas Gupta, Srdan Verstovsek, Ruben A. Mesa, Carole Brennan Miller, Candido E. Rivera, Angela Fleischman, Swati Goel, Mark L Heaney, Casey O`Connell, Murat Arcasoy, Yafeng Zhang, Jun Kawashima, Tomas Ganz and Carrie Baker Brachmann. Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients; 2018 Jan. (Blood). Zhenya Senyak, Ruben A. Mesa, Nicolaus Kroeger, Koen Van Besien, Wael Saber, Richard T. Silver, Attilio Orazi, Jeanne Palmer, Claire N. Harrison, Srdan Verstovsek, Uday Popat, Michelle J Woerhle, Ann Brazeau, Barbara Van Husen, Martin Prager, Chris Harper, Beatrice Larroque and Robyn Marie Scherber. Results from the Myeloproliferative Neoplasm Patient Care Survey: Patient Care Opportunities and Challenges; 2018 Jan. (Blood). Robyn M. Scherber, Holly L. Geyer, Gina Mazza, Blake T. Langlais, Amylou C. Dueck, Jeanne Palmer, Leslie Padrnos, Angela Fleischman and Ruben A. Mesa. Tobacco Use in the Myeloproliferative Neoplasms: Patient Behavior, Opinions, and Care; 2018 Jan. (Blood). Blake T. Langlais, Gina Mazza, Crystal S. Langlais, Heidi E. Kosiorek, Holly L. Geyer, Ruben A. Mesa, Robyn M. Scherber and Amylou C. Dueck. Utilization of Patient-Reported Outcomes in Myeloproliferative Neoplasm Clinical Trials Registered at Clinicaltrials.Gov; 2018 Jan. (Blood). Jeanne Palmer, Heidi E. Kosiorek, Christine Wolschke, Veena D. S. Fauble, Richard Butterfield III, Holly Geyer, Robyn M. Scherber, Amylou C. Dueck, Allison Gathany, Ruben A. Mesa and Nicolaus Kroeger. Assessment of Quality of Life Following Allogeneic Stem Cell Transplant for Myelofibrosis; 2018 Jan. (Blood). Srdan Verstovsek, Jingbo Yu, Jonathan K. Kish, Dilan Chamikara Paranagama, Jill Kaufman, Jessica Chung, Michael R. Grunwald, Philomena Colucci and Ruben A. Mesa. Real-World Risk Assessment and Treatment of Patients with Myelofibrosis at Community Oncology Practices in the United States; 2018 Jan. (Blood). Krisstina L. Gowin, Blake T. Langlais, Denise Millstine, Heidi E. Kosiorek, Jennifer Huberty, Ryan Eckert and Ruben A. Mesa. Survey of Integrative Medicine in Myeloproliferative Neoplasms (The SIMM Study-2); 2018 Jan. (Blood). Holly L. Geyer, Robyn M. Scherber, Gina Mazza, Blake Langlais, Leslie Padrnos, Jeanne Palmer, Amylou C. Dueck and Ruben A. Mesa. Prevalence and Risk Factors for Opioid-Related Complications in Patients with Myeloproliferative Neoplasms: An International Survey of 502 Patients By the MPN Quality of Life Study Group; 2018 Jan. (Blood). Ruben A. Mesa, Francisco Cervantes, Claire N. Harrison, Adam J. Mead, Alessandro M. Vannucchi, Srdan Verstovsek, Lixia Wang, Tanya Granston and John Mascarenhas. Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2); 2018 Jan. (Blood). Holly L. Geyer, Robyn M. Scherber, Gina Mazza, Blake T. Langlais, Ruben A. Mesa, Leslie Padrnos, Amylou C. Dueck and Jeanne Palmer. Addressing the Adequacy of Current MPN Pain Management Strategies: An International Survey of 502 Patients By the MPN Quality of Life Study Group; 2018 Jan. (Blood). Anas Al-Janadi, Ruben A. Mesa, Philomena Colucci, Shreekant Parasuraman, Dilan Chamikara Paranagama and Michael Richard Grunwald. Characteristics Associated with Hydroxyurea Treatment Change in Patients with Polycythemia Vera: An Analysis from the Reveal Study; 2018 Jan. (Blood). Ivy Altomare, Aaron T. Gerds, David Lessen, Philomena Colucci, Shreekant Parasuraman, Dilan Chamikara Paranagama and Ruben A. Mesa. Correlation between MPN-SAF TSS and EORTC QLQ-C30 Scores in Patients with PV: Data from the Reveal Study; 2018 Jan. (Blood). Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis. doi: 10.1200/JCO.2017.73.4418. Epub 2017 Sep 20. PMID:28930494; 2017 Dec. (J Clin; vol. 35, no. 34). Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, Mathias J, Komatsu N, Boothroyd RN, Spierer A, Perez Ronco J, Taylor-Stokes G, Waller J, Mesa RA. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. doi: 10.1007/s002770173082y. Epub 2017 Aug 5. PMID: 28780729; 2017 Oct. (Ann Hematol; vol. 96, no. 10). Verstovsek S, Mesa RA, Salama ME, Li L, Pitou C, Nunes FP, Price GL, Giles JL, D'Souza DN, Walgren RA, Prchal JT. A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. doi: 10.1016/j.leukres.2017.08.010. Epub 2017 Aug 31. PMID:28934680; 2017 Oct. (Leuk Res; vol. 61). Ellis MH, KorenMichowitz M, Lavi N, Vannucchi AM, Mesa R, Harrison CN. Ruxolitinib for the management of myelofibrosis: Results of an international physician survey. doi: 10.1016/j.leukres.2017.08.002. Epub 2017 Aug 10. PMID: 28843161; 2017 Oct. (Leuk Res; vol. 61). Geyer H, Mesa RA. Approach to MPN Symptom Assessment. doi: 10.1007/s1189901703995. Review. PMID: 28942516; 2017 Oct. (Curr Hematol Malig Rep; vol. 12, no. 5). Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, Houlton A, Alimam S, Ewing J, Wood M, Chen F, Coppell J, Panoskaltsis N, Knapper S, Ali S, Hamblin A, Scherber R, Dueck AC, Cross NCP, Mesa R, McMullin MF. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. doi: 10.1182/blood201705785790. Epub 2017 Aug 9. PMID: 29074595; 2017 Oct. (Blood; vol. 130, no. 17). Pemmaraju N, Mesa RA, Majhail NS, Thompson MA. The use and impact of Twitter at medical conferences: Best practices and Twitter etiquette. doi: 10.1053/j.seminhematol.2017.08.003. Epub 2017 Aug 24. Review. PMID: 29153078; 2017 Oct. (Semin Hematol; vol. 54, no. 4). Verstovsek S, Courby S, Griesshammer M, Mesa RA, Brachmann CB, Kawashima J, Maltzman JD, Shao L, Xin Y, Huang D, Bajel A. A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. doi: 10.1016/j.leukres.2017.05.002. Epub 2017 May 30. PMID: 28622623; 2017 Sep. (Leuk Res; vol. 60). Miller CB, Komrokji RS, Mesa RA, Sun W, Montgomery M, Verstovsek S. Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I. [Epub ahead of print] PMID:28606598 DOI:10.1016/j.clml.2017.05.015; 2017 Aug. (Clin Lymphoma Myeloma Leuk; vol. 17, no. 8). Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Epub 2017 June 08 PMID:28602585 DOI:10.1016/S2352-3026(17)30088-1; 2017 Jul. (Lancet Haematol; vol. 4, no. 7). Gowin K, Kosiorek H, Dueck A, Mascarenhas J, Hoffman R, Reeder C, Camoriano J, Tibes R, Gano K, Palmer J, Mesa R. Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. Epub 2017 June 13 PMID:28646676 DOI:10.1016/j.leukres.2017.06.005; 2017 Jun. (Leuk Res; vol. 60). Steffen Koschmieder, Michael Koehler, Paola Guglielmelli, Ruben A. Mesa, Lynda Foltz, Tina Flindt, Jonathan Mathias, Norio Komatsu, Robert N. Boothroyd, Amber Spierer, Julian Perez Ronco, Gavin Taylor-Stokes, John Waller, Claire N. Harrison. TREATMENT AND MANAGEMENT OF PATIENTS WITH MPNS?FINDINGS FROM THE INTERNATIONAL MPN LANDMARK SURVEY; 2017 Jun. Krisstina Gowin, Denise Millstine, Heidi Kosiorek, Blake Langlais, Jennifer Huberty, Ryan Eckert, Ruben Mesa. THE SIMM STUDY: SURVEY OF INTEGRATIVE MEDICINE IN MYELOPROLIFERATIVE NEOPLASMS; 2017 Jun. Suliman Al-Fayoumi, John Mascarenhas,Ronald Hoffman, Moshe Talpaz, Aaron T. Gerds, Brady Stein, Vikas Gupta, Anita Szoke, Mark Drummond, Alexander Pristupa, Huafeng Zhou, Robert Daly, Jennifer A. Callahan, Jack W. Singer, Jason Gotlib, Catriona Jamieson, Claire Harrison, Ruben Mesa, Srdan Verstovsek. PK/PD MODELING COMPARING DIVIDED DOSING (200 MG TWICE DAILY) VS SINGLE DOSING (400 MG ONCE DAILY) OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS ON THE PERSIST-2 PHASE 3 TRIAL; 2017 Jun. Jason R. Gotlib, Jean-Jacques Kiladjian, John V. Catalano, Timothy Devos, Miklos Egyed, Andrzei Hellman, Donal P. McLornan, Kazuya Shimoda, Elliott F. Winton, Wei Deng, Ronald L. Dubowy, Julia D. Maltzman, Francisco Cervantes, Ruben A. Mesa. PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS RUXOLITINIB IN JAK INHIBITOR NAIVE PATIENTS WITH MYELOFIBROSIS: RESULTS OF THE SIMPLIFY-1 STUDY; 2017 Jun. Lynda Foltz, Steffen Koschmieder, Claire N. Harrison, Paola Guglielmelli, Tina Flindt, Michael Koehler, Jonathan Mathias, Norio Komatsu, Robert N. Boothroyd, Amber Spierer, Julian Perez Ronco, Gavin Taylor-Stokes, John Waller, Ruben A. Mesa. PERCEPTION OF SYMPTOM BURDEN AND TREATMENT GOALS BETWEEN PHYSICIANS AND PATIENTS WITH MPNS: AN ANALYSIS FROM THE INTERNATIONAL MPN LANDMARK SURVEY; 2017 Jun. Moshe Talpaz, John Mascarenhas, Ronald Hoffman, Aaron T. Gerds, Brady Stein, Vikas Gupta, Anita Szoke, Mark Drummond, Alexander Pristupa, Tanya Granston, Robert Daly, Suliman Al-Fayoumi, Jennifer A. Callahan, Jack W. Singer, Jason Gotlib, Catriona Jamieson, Claire Harrison, Ruben Mesa, Srdan Verstovsek. PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), INCLUDING RUXOLITINIB, IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) AND BASELINE THROMBOCYTOPENIA: FOCUS ON ANEMIA IN THE PHASE 3 PERSIST-2 TRIAL; 2017 Jun. Claire Harrison, John Mascarenhas, Ronald Hoffman, Moshe Talpaz, Aaron T. Gerds, Brady Stein, Vikas Gupta, Anita Szoke, Mark Drummond, Alexander Pristupa, Tanya Granston, Robert Daly, Suliman Al-Fayoumi, Jennifer A. Callahan, Jack W. Singer, Jason Gotlib, Catriona Jamieson, Ruben Mesa, Srdan Verstovsek. PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), IN PATIENTS WITH MYELOFIBROSIS (MF) AND BASELINE (BL) THROMBOCYTOPENIA: FOCUS ON RUXOLITINIB (RUX)-TREATED PATIENTS IN THE PHASE 3 PERSIST-2 TRIAL; 2017 Jun. Robyn Scherber, Holly Geyer, Amylou Dueck, Carol Johnston, Blake Langlais, Leslie Padrnos, Jeanne Palmer, Angela Fleischman, Ruben Mesa. NUTRITIONAL NEEDS AND PREFERENCES OF MYELOPROLIFERATIVE NEOPLASM PATIENTS: PHASE IA OF THE NUTRIENT STUDY; 2017 Jun. Robyn Scherber, Heidi Kosiorek, Holly Geyer, Srdan Verstovsek, Blake Langlais, Leslie Padrnos, Jeanne Palmer, Amylou Dueck, Angela Fleischman, Ruben Mesa. NUTRITION IN MYELOFIBROSIS: CORRELATES FROM THE COMFORT-1 STUDY; 2017 Jun. Jennifer Huberty , Ryan Eckert , Krisstina Gowin , Brenda Ginos , Heidi Kosiorek , Amylou Dueck , Linda Larkey , Ruben Mesa. DEVELOPMENT AND DESIGN OF A RANDOMIZED CONTROLLED TRIAL USING ONLINE YOGA FOR SYMPTOM MANAGEMENT IN MYELOPROLIFERATIVE NEOPLASM PATIENTS; 2017 Jun. Amylou Dueck , Robyn Scherber , Heidi Kosiorek , Blake Langlais , Leslie Padrnos , Jeanne Palmer , Srdan Verstovsek , Jeff Sloan , Geyer Holly , Ruben Mesa. DETERMINING MEANINGFUL CHANGE IN THE MYELOFIBROSIS SYMPTOM ASSESSMENT FORM (MFSAF) V2.0 USING A COMBINATION OF DISTRIBUTION- AND ANCHOR-BASED APPROACHES IN THE COMFORT-I TRIAL; 2017 Jun. Geyer H, Scherber R, Kosiorek H, Verstovesek S, Langlais B, Padrnos L, Palmer J, Dueck A, Mesa R. Correlations between inflammatory biomarkers and individual symptoms expressed by myelofibrosis patients in the COMFORT-I Trial: Analysis of baseline associations and changes over time; 2017 Jun. Robyn Scherber, Heidi Kosiorek, Holly Geyer, Srdan Verstovsek, Jeff Sloan, Blake Langlais, Leslie Padrnos, Jeanne Palmer, Angela Fleischman, Amylou Dueck, Ruben Mesa. BASELINE QUALITY OF LIFE INDEPENDENTLY PREDICTS OVERALL SURVIVAL IN THE MYELOFIBROSIS: KEY INSIGHTS FROM THE COMFORT-I STUDY; 2017 Jun. Gwaltney C, Paty J, Kwitkowski VE, Mesa RA, Dueck AC, Papadopoulos EJ, Wang L, Feliciano J, Coons SJ. Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials. [Epub ahead of print] PMID:28544906 DOI:10.1016/j.leukres.2017.05.012; 2017 May. (Leuk Res; vol. 59). Ryan Eckert, Jennifer Huberty, Amylou Dueck, Heidi Kosiorek, Linda Larkey, and Ruben A Mesa. A Pilot Study of Online Yoga to Improve Fatigue and Quality of Life in Myeloproliferative Neoplasm Patients; 2017 Jan. (Blood; vol. 130). Amylou C. Dueck, John Mascarenhas, Heidi Elizabeth Kosiorek, Abdulraheem Yacoub, Josef T. Prchal, Dmitriy Berenzon, Maria R. Baer, Ellen K Ritchie, Richard T Silver, Craig M. Kessler, Elliott F. Winton, Maria Chiara Finazzi, Alessandro Rambaldi, Alessandro M. Vannucchi, David S. Leibowitz, Damiano Rondelli, Murat O. Arcasoy, Rosalind Catchatourian, Joseph Vadakara, Vittorio Rosti, Elizabeth Hexner, Marina Kremyanskaya, Alicia Orellana, Lonette Sandy, Joseph Tripodi, Vesna Najfeld, Mohamed E. Salama, Rona Singer Weinberg, Raajit K. Rampal, Ronald Hoffman and Ruben A Mesa . Single-Arm Phase II Trial of Pegylated Interferon Alpha 2a in Patients with High-Risk Essential Thrombocythemia or Polycythemia Vera Resistant or Intolerant to Hydroxyurea: MPN Symptom Impact & Quality of Life Results of the Myeloproliferative Disorders; 2017 Jan. (Blood; vol. 130). Gowin KL, Millstine D, Kosiorek HE, Langlais B, Huberty J, Eckert R, Mesa RA. Supportive care and symptom burden in patients with myeloproliferative neoplasms. Abstract No 21684; 2017 Jan. (J Clin Oncol; vol. 35, no. Sup). Gerds AT, Tauchi T, Ritchie EK, Deininger MWN, Jamieson CHM, Mesa RA, Heaney ML, Komatsu N, Minami H, Su Y, Shaik MN, Zhang X, DiRienzo C, Zeremski M, Woolfsen A, Chan G, Talpaz M. Phase I/II trial of glasdegib in patients with primary or secondary myelofibrosis. Abstract No 7061; 2017 Jan. (J Clin Oncol; vol. 35, no. Sup). Mesa RA, Kiladjian J-J, Catalano JV, Devos T, Egyed M, Hellman A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib JR. Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF). Abstr 7000; 2017 Jan. (J Clin Oncol; vol. 35, no. Sup). Huberty J, Eckert R, Gowin KL, Ginos BF, Kosiorek HE, Dueck AC, Larkey L, Mesa RA. Online yoga as a non-pharmacologic symptom management approach in myeloproliferative neoplasms. Abstr e21704; 2017 Jan. (J Clin Oncol; vol. 35, no. Sup). Allison Scotch, Robyn M. Scherber, Marlene Bruso, Heidi Elizabeth Kosiorek, Amylou C. Dueck, Holly Geyer, Veena D. S. Fauble, Alessandro M. Vannucchi, Ana Kerguelen Fuentes, Christen Lykkegaard Andersen, Elisabeth Ejerblad, Gunnar Birgegard, Peter L. Johansson, Bjorn Andreasson, David M Ross, Federico Sackman, Jean-Loup Demory, Constantine S. Tam, Jan J. Michiels, Deepti Radia, Joanne Ewing, Frances Wadelin, Robert N. Lown, Mary Frances McMullin, Wunna Swe, Jonathan O. Cullis, Nigel Sargant, Paul Moreton, Catherine Cargo, Mallika Sekhar, Satareh Shekouhi, and Ruben A Mesa. Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial; 2017 Jan. (Blood; vol. 130). Aaron T. Gerds, Tetsuzo Tauchi, Ellen K. Ritchie, Michael W. Deininger, Catriona HM Jamieson, Ruben Mesa, Mark Lawrence Heaney, Norio Komatsu, Hironobu Minami, M. Naveed Shaik, Xiaoxi Zhang, Christine DiRienzo, Mirjana Zeremski, Geoffrey Chan, and Moshe Talpaz. Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis; 2017 Jan. (Blood; vol. 130). Alessandro Rambaldi, Alessandra Iurlo, Alessandro M. Vannucchi, Richard Noble, Nikolas von Bubnoff, Attilio Guarini, Andrzej Hellmann, Bruno Martino, Antonio Pezzutto, Giuseppe Carli, Marianna De Muro, Paolo Di Bartolomeo, Mary Frances Frances McMullin, Nathalie Cambier, Jean-Pierre Marolleau, Ruben A Mesa, Raoul Tibes, Paolo Bettica, Sara Manzoni, and Silvia DI Tollo. A Two-Part Study of Givinostat in Patients with Polycythemia Vera: The Maximum Tolerated Dose Selection and the Proof of Concept Final Results; 2017 Jan. (Blood; vol. 130). Jean-Jacques Kiladjian, Srdan Verstovsek, Martin Griesshammer, Tamas Masszi, Simon Durrant, Francesco Passamonti, Claire N. Harrison, Fabrizio Pane, Pierre Zachee, Keita Kirito, Carlos Besses, Masayuki Hino, Ana Ines Varela, Carole B. Miller, Elisa Rumi, Vittorio Rosti, Igor Wolfgang Blau, Ruben A Mesa, Tuochuan Dong, Nathalie Francillard, Mary Laughlin, and Alessandro M. Vannucchi. Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV); 2017 Jan. (Blood; vol. 130). Raoul Tibes, Heidi Elizabeth Kosiorek, Amylou Dueck, Jeanne Palmer, James L. Slack, Emily Ann Knight, Saman Khalid Hashmi, James M. Bogenberger, Darci Zblewski, William J. Hogan, Mark R. Litzow, Ruben A Mesa, James M. Foran, Lisa Sproat, and Aref Al-Kali. Phase I/IB Study of Azacitidine and Hedgehog Pathway Inhibition with Sonidegib (LDE225) in Myeloid Malignancies; 2017 Jan. (Blood; vol. 130). Jeanne Palmer, Tania Jain, Katie L. Kunze, Daniel K. Partain, Nandita Khera, Lisa Sproat, Pierre Noel, James L. Slack, Vivek Roy, Jose F. Leis, William J. Hogan, Ayalew Tefferi, Veena D. S. Fauble, Mrinal M. Patnaik, Heidi Elizabeth Kosiorek, and Ruben A Mesa. Pre-Transplantation Predictors of Survival in Patients Undergoing Allogeneic Stem Cell Transplant for Myelofibrosis; 2017 Jan. (Blood; vol. 130). Eric Padron, Amy E. DeZern, Sandrine Niyongere, Markus Christian Ball, Maria Balasis, Hanadi Ramadan, Jeffrey E. Lancet, Alan F List, Ruben A Mesa, Gail J. Roboz, David P. Steensma, Mikkael A. Sekeres, and Rami S. Komrokji. Promising Results of a Phase 1/2 Clinical Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia; 2017 Jan. (Blood; vol. 130). eslie Padrnos, Robyn M. Scherber, Blake T. Langlais, Amylou Dueck, Jennifer Huberty, Holly L. Geyer, Krisstina L. Gowin, Heidi Kosiorek, Marlene Bruso, Zhenya Senyak, Matthew M Clark, Michael Boxer, Mary Cotter, Claire N. Harrison, and Ruben A Mesa. Myeloproliferative Neoplasms and Depressive Symptoms, Diagnosis, and Associations; 2017 Jan. (Blood; vol. 130). Leslie Padrnos, Heidi Kosiorek, Robert M Bennett III, Amylou Constance Dueck, Krisstina L. Gowin, Robyn M. Scherber, Holly L. Geyer, Jeanne Palmer, Donald Northfelt, Joseph R Mikhael, Nandita Khera, and Ruben A Mesa. Duration Matters: Impact of Time from Diagnosis on Symptoms in Patients with Hematologic Malignancies; 2017 Jan. (Blood; vol. 130). Michael Richard Grunwald, Ivy Altomare, John M. Burke, Aaron T. Gerds, Mark A. Walshauser, Michael R. Savona, David J Kuter, Brady Lee Stein, Stephen Oh, Philomena Colucci, Ahmad B. Naim, Dilan Chamikara Paranagama, and Ruben A Mesa. Examining the Treatment Patterns and Blood Counts Among Patients with Polycythemia Vera Treated with Hydroxyurea in the United States: An Analysis from the Reveal Study; 2017 Jan. (Blood; vol. 130). Michael Richard Grunwald, John M. Burke, David J Kuter, Aaron T. Gerds, Brady Lee Stein, Michael R. Savona, Mark A. Walshauser, Ahmad B. Naim, Philomena Colucci, Dilan Chamikara Paranagama, and Ruben A Mesa. Patient-Reported Symptom Burden and Peripheral Blood Counts Among Patients with Polycythemia Vera: An Analysis from the Reveal Study; 2017 Jan. (Blood; vol. 130). Tania Jain, Katie L. Kunze, Daniel K. Partain, Heidi Kosiorek, Vivek Roy, Nandita Khera, James L. Slack, Mrinal M. Patnaik, William J. Hogan, Pierre Noel, Veena D. S. Fauble, Jose F. Leis, Lisa Sproat, Ruben A Mesa, and Jeanne Palmer. Transfusion Dependence at Day +100 Predicts Poorer Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation for Myelofibrosis; 2017 Jan. (Blood; vol. 130). Ryan P Topping, Michael W. Deininger, John Mascarenhas, Ruben A Mesa, Brady Lee Stein, Kevin L Obholz, Jason J Everly, and Srdan Verstovsek. Variance between Experts and Oncology Healthcare Providers in Managing Polycythemia Vera and Myelofibrosis: Analysis of an Online Treatment Decision Support Tool; 2017 Jan. (Blood; vol. 130). Amylou C. Dueck, Chad Gwaltney, Wen-Hung Chen, Lixia Wang, Renee Pierson, Jeremiah Trudeau, Sonya Eremenco, Stephen Joel Coons, and Ruben A Mesa. Quantitative Testing of the Myelofibrosis Symptom Assessment Form Version 4.0, a Harmonized Patient-Reported Outcome Measure for Collecting Key Secondary Endpoint Data in Myelofibrosis Clinical Trials; 2017 Jan. (Blood; vol. 130). Robyn M. Scherber, Blake T. Langlais, Holly Geyer, Amylou Dueck, Heidi Kosoriek, Carol Johnston, Leslie Padrnos, Jeanne Palmer, Angela G. Fleischman, and Ruben A Mesa. Nutrition and Supplement Use Characteristics in the Myeloproliferative Neoplasms: Results from the Nutrient Survey; 2017 Jan. (Blood; vol. 130). Krisstina L. Gowin, Blake T. Langlais, Heidi Elizabeth Kosiorek, Amylou Dueck, Denise Millstine, Jennifer Huberty, Ryan Eckert, Leslie Padrnos, Robyn M. Scherber, and Ruben A Mesa. Sleep and Psychiatric Disturbance in Chronic Philadelphia Negative Myeloproliferative Neoplasms; 2017 Jan. (Blood; vol. 130). Jingbo Yu, Dilan Chamikara Paranagama, Holly L. Geyer, Shreekant V. Parasuraman, and Ruben A. Mesa. Role of Symptom Burden in Disability Leave Among Patients with Myeloproliferative Neoplasms (MPNs): Findings from the Living with MPN Patient Survey; 2017 Jan. (Blood; vol. 130). Blake T. Langlais, Heidi Kosiorek, Holly Geyer, Robyn M. Scherber, Ruben A Mesa, and Amylou C. Dueck. Quality of Life and Symptom Burden Among Patients with Myeloproliferative Neoplasms: Do Symptoms Impact Quality of Life?; 2017 Jan. (Blood). Claire N. Harrison, Ruben A Mesa, Catriona Jamieson, John Hood, Julie Bykowski, Giulio Zuccoli, and James Brewer. Case Series of Potential Wernicke's Encephalopathy in Patients Treated with Fedratinib; 2017 Jan. (Blood; vol. 130). Geyer H, Kosiorek H, Dueck A, Slot S, Zweegman S, Kiladjian JJ, Boekhorst P, Schouten H, Sackmann F, Fuentes A, Hernandez-Maraver D, Pahl H, Stegelmann F, Doehner K, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison C, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson P, Barosi G, Passamonti F, Andreasson B, Samuelsson J, Birgegard G, Sun X, Xu J, Zhang P, Xu Z, Barbui T, Barbui T, Senyak Z, Grieshammer M, Rambaldi A, Ferrari M, Lehmann T, Scherber R, Mesa R. Development of an mf patient reported outcome (pro) tool for fda qualification: comprehensive literature search and physician cognitive debriefing results; 2016 Jun. (Haematologica; vol. 101, no. S1). Geyer H, Kosiorek H, Dueck A, Slot S, Zweegman S, Mesa RA, Kiladjian J-J, et al. ReTHINK: A randomized, double-blind, placebo-controlled, multicenter, phase 3 study of ruxolitinib in early myelofibrosis patients; 2016 Jun. Harrison CN, Egyed M, Szoke A, Suvorov A, Perkins A, Mayer J, Ganly P, Schouten HC, Tosi P, Farber CM, Zachee P, Scheid C, Dean JP, Zhou H, Kiladjian J-J, Vannucchi AM, Nangalia J, Mead A, Mesa RA. Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Outcomes in patients (pts) with baseline (BL) thrombocytopenia; 2016 Jun. Mesa RA, Egyed M, Szoke A, Suvorov A, Perkins A, Mayer J, Ganley P, Schouten HC, Tosi P, Farber CM, Zachee P, Scheid C, Dean JP, Granston T, Kiladjian J-J, Vannucchi AM, Nangalia J, Mead A, Harrison CN. Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): 60 week follow-up of the phase III PERSIST-1 trial; 2016 Jun. Gupta V, Verstovsek S, Mesa RA, Gotlib JR, DiPersio JF, Catalano JV, Deininger MWN, Brennan Miller C, Silver RT, Talpaz M, Winton EF, Huling Harvey J, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Kornacki D, Sun K, Kantarjian HM, COMFORT-I Investigators. Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I; 2016 Jun. Harrison CN, Egyed M, Szoke A, Suvorov A, Perkins A, Mayer J, Ganly P, Schouten HC, Tosi P, Farber CM, Zachee P, Scheid C, Dean JP, Zhou H, Kiladjian J-J, Vannucchi AM, Nangalia J, Mead A, Mesa RA. Outcomes in patients with myelofibrosis and RBC-transfusion dependence in the phase III PERSIST-1 study of pacritinib vs. best available therapy; 2016 Jun. Scherber R, Dueck A, Geyer H, Kosiorek H, Kiladjian JJ, Slot S, Zweegman S, Boekhorst P, Schouten H, Sackmann F, Fuentes A, Hernandez-Maraver D, Pahl H, Stegelmann F, Doehner K, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison C, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson P, Barosi G, Vannucchi A, Passamonti F, Andreasson B, Samuelsson J, Birgegard G, Sun X, Xu J, Zhang P, Xu Z, Barbui T, Barbui T, Senyak Z, Grieshammer M, Rambaldi A, Ferrari M, Lehmann T, Mesa R. Symptoms, risk classification, and spleen size in jak2 inhibitor-naive myelofibrosis: implications for jak2 inhibitor treatment; 2016 Jun. (Haematologica; vol. 101, no. S1). Harrison C, Mead A, Panchal A, Fox S, Yap C, Houlton A, Aliman S, Wood M, Chen F, Coppell J, Panoskaltsis N, Scherber R, Geyer H, Dueck A, Mesa R, McMullin MF. Ruxolitinib compared with best available therapy for essential thrombocythaemia patients resistant or intolerant to hydroxycarbamide in majic - an investigator lead randomized trial; 2016 Jun. (Haematologica; vol. 101, no. S1). Huberty J, Eckert R, Gowin K, Dueck A, Mesa R. Online streaming yoga is a feasible non-pharmacologic management strategy in myeloproliferative neoplasm patients; 2016 Jun. (Haematologica; vol. 101, no. S1). Verstovsek S, Mesa RA, Gotlib JR, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H. Long-term outcomes of ruxolitinib (rux) therapy in patients (pts) with myelofibrosis (mf): 5-year final efficacy and safety analysis from comfort-I; 2016 Jun. (Haematologica; vol. 101, no. S1). Geyer H, Scherber R, Kosiorek H, Dueck A, Kiladjian JJ, Slot S, Zweegman S, Boekhorst P, Schouten H, Sackmann F, Fuentes A, Hernandez-Maraver D, Pahl H, Stegelmann F, Doehner K, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison C, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson P, Barosi G, Vannucchi A, Passamonti F, Andreasson B, Samuelsson J, Birgegard G, Sun X, Xu J, Zhang P, Xu Z, Barbui T, Barbui T, Senyak Z, Grieshammer M, Rambaldi A, Ferrari M, Lehmann T, Mesa R. Impact of splenomegaly on mpn symptoms and association with clinical features: an analysis by the mpn quality of life international study group; 2016 Jun. (Haematologica; vol. 101, no. S1). Hoyer J, Mesa R, Oliveira J. Low level jak2 v617f positivity in a patient with hemoglobin (hb) olympia; 2016 May. (International Journal of Laboratory Hematology; vol. 38). Mesa RA. Role for new drugs in et and pv; 2016 May. (Leukemia Research; vol. 44). Partain DK, Damlaj M, Litzow MR, Al-kali A, Hogan WJ, Hashmi SK, Gangat N, Foran J, Slack JL, Palmer J, Mesa RA, Patnaik MS. Incidence and outcomes of primary engraftment failure in patients undergoing reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for primary myelofibrosis; 2016 Mar. (Biology of Blood and Marrow Transplantation; vol. 22, no. 3). Verstovsek S, Gupta V, Gotlib JR, Mesa RA, Vannucchi AM, Kiladjian J-J, Cervantes F, Sun W, Gao J, Dong t, Naim A, Gopalakrishna P, Harrison CN. A pooled overall survival (OS) analysis of 5-year data from COMFORT-I and COMFORT-II trials of ruxolitinib for the treatment of myelofibrosis (MF); 2016 Jan. (Blood; vol. 128). Scherber RM, Senyak Z, Kosiorek HE, Dueck AC, Clark MM, Boxer M, Goldstein MA, Cotter M, McCallister A, VanHusen B, Harrison CN, Mesa RA. Treating depression in the myeloproliferative neoplasms: the role and implications of poorly controlled symptoms and psychosocial factors; 2016 Jan. (Blood; vol. 128). Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, Mathias J, Komatsu N, Boothroyd RN, Spierer A, Ronco JP, Taylor-Stokes G, Waller J, Mesa RA. The impact of myeloproliferative neoplasms (MPNs) on patients` quality of life and productivity: results from the international MPN landmark survey; 2016 Jan. (Blood; vol. 128). Bogenberger JM, Hansen N, Delman D, Sproat L, Palmer J, Mesa R, Tibes R. Synergistic activity of lysine deacetylase inhibitors and microtubule-targeting agents in AML; 2016 Jan. (Blood; vol. 128). Scherber RM, Geyer H, Dueck AC, Kosiorek HE, Kiladjian J-J, Slot S, Zweegman S, Boekhorst PT, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernandez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn J-Y, Harrison CN, Radia D, Muxi PJ, Maldonado NI, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Andreasson B, Ferarri M, Rambaldi A, Samuelsson J, Birgegard G, Cannon K, Sun X, Xu J, Zhang P, Xu Z, Mesa RA. Symptom burden as primary driver for therapy in patients with myelofibrosis: an analysis by MPN international quality of life study group; 2016 Jan. (Blood; vol. 128). Rampal RK, Mascarenhas JO, Kosiorek HE, Berenzon D, Hexner E, Abboud CN, Kremyanskaya M, Weinberg RS, Salama ME, Tognoni G, Prosperini G, DiLelio A, Serone E, Marfisi L, Sandy L, Heaney ML, Levine RL, Mesa RA, Dueck AC, Hoffman R. Safety and efficacy of combines ruxolitinib and decitabine in patients with blast-phase MPN and post-MPN AML: results of a phase I study (myeloproliferative disorders research consortium 109 trial); 2016 Jan. (Blood; vol. 128). Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Dean JP, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S. Results of the persist-2 phase 3 study of pacritinib (PAC) versus best available therapy (BAT), including ruxolitinib (RUX), in patients (pts) with myelofibrosis (MF) and platelet counts less than 100,000 per microliter; 2016 Jan. (Blood; vol. 128). Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Perkins A, Mayer J, Ganly P, Schouten HC, Tosi P, Farber CM, Zachee P, Kiladjian J-J, Nangalia J, Dean JP, Zhou H, Singer JW, Mesa RA, Harrison CN. Relationship of JAK2 V617F allelic burden (AB) to demographics, disease characteristics, and response to therapy in Persist-1, a randomized phase III study of pacritinib (PAC) versus best available therapy (BAT) in patients (pts) with primary and seconda; 2016 Jan. (Blood; vol. 128). Palmer J, Kosiorek H, Fauble VDS, Geyer H, Dueck AC, Mesa R. Quality of life following allogeneic stem cell transplant for MF; 2016 Jan. (Blood; vol. 128). Moyo TK, Sochacki A, Ayers GD, Byrne MT, Strickland SA, Mohan SR, Harrison J, Berry LD, Dudley CV, Severs R, Dugger L, Miskin HP, Cavers A, Sportelli P, Michaelis LC, Mesa RA, Savona MR. Preliminary results from a phase I dose escalation trial of ruxolitinib and the PI3K delta inhibitor TGR-1202 in myelofibrosis; 2016 Jan. (Blood; vol. 128). Verstovesek S, Talpaz M, Ritchie EK, Wadleigh M, Odenike O, Jamieson C, Stein B, Rivera CE, Uno T, Mesa RA. Phase 1/2 study of NS-018, an oral JAK2 inhibitor, in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (postPV MF), or post-essential thrombocythemia myelofibrosis (postET MF); 2016 Jan. (Blood; vol. 128). Huberty J, Eckert R, Gowin KL, Ginos B, Kosiorek HE, Dueck AC, Mesa RA. Online-streamed yoga as a non-pharmacologic symptom management approach in myeloproliferative neoplasms; 2016 Jan. (Blood; vol. 128). Scotch AH, Scherber RM, Zhang N, Kosiorek HE, Dueck AC, Geyer H, Fauble V, Vannucchi AM, Kerguelen Fuentes A, Kykkegaard Andersen C, Ejerblad E, Birgegard G, Johansson PL, Andreasson B, Ross DM, Sackmann F, Demory J-L, Tam CS, Michiels JJ, Radia D, Mahalakshmi M, Jennings D, Ewing JC, Wadelin F, Lown RN, Drew V, Hudson J, McMullin MF, Swe W, Cullis JO, Sargant N, Moreton P, Kilner MF, Cargo C, Sekhar M, Shekouhi S, Mesa RA. Myeloproliferative neoplasm quality of life (MPN-QOL) study group: interim results from the MPN experimental assessment of symptoms by utilizing repetitive evaluation (MEASURE) trial; 2016 Jan. (Blood; vol. 128). Mascarenas JO, Prchal JT, Rambaldi A, Mesa RA, Berenzon D, Yacoub A, Harrison CN, McMullin MF, Vannucchi AM, Ewing JC, O`Connell CL, Kiladjian J-J, Mead A, Winton EF, Leibowitz DS, DeStefano V, Arcasoy MO, Kessler CM, Catchatorian R, Rondelli D, Silver RT, Ritchie EK, Nagler A, Kremyanskaya M, Schlenk RF, Weinberg Rs, Salama ME, Tognoni G, Prosperinie G, DiLelio A, Serone E, Marfisi L, Kleczko J, Kosiorek HE, Barbui T, Dueck AC, Hoffman R. Interim analysis of the myeloproliferative disorders research consortium (MPD-RC) 112 global phase III trial of front line pegylated interferon alpha-2a vs. hydroxyurea in high risk polycythemia vera and essential thrombocythemia; 2016 Jan. (Blood; vol. 128). Mesa RA, Hoffman R, Kosiorek HE, Prchal JT, Harrison CN, McMullin MF, Yacoub A, Rambaldi A, Berenzon D, VAnnucchi AM, Ewing JC, O`Connell CL, Kiladjian J-J, Mead A, Winton EF, Liebowtiz DS, DeStefano V, Arcasoy MO, Kessler CM, Catchatorian R, Rondelli D, Silver RT, Ritchie EK, Nagler A, Kremyanskaya M, Schlenk RF, Weinberg RS, Salama ME, Tognoni G, Prosperini G, DiLelio A, Serone E, Marfisi L, Orellana A, Barbui T, Dueck AC, Mascarenhas JO. Impact on MPN symptoms and quality of life of front line pegylated interferon alpha-2a vs. hydroxyurea in high risk polycythemia vera and essential thrombocythemia: interim analysis results of myeloproliferative disorders research consortium (MPD-Rc) 1; 2016 Jan. (Blood; vol. 128). Eckert R, Huberty J, Gowin KL, Ginos B, Kosiorek HE, Dueck AC, Mesa RA. Impact of weight on symptom burden outcomes in myeloproliferative neoplasm patients participating in an online yoga intervention; 2016 Jan. (Blood; vol. 128). Yu J, Parasuraman S, Paranagama D, Naim A, Dubinski D, Bai A, Mesa R. Impact of myeloproliferative neoplasms on patients` employment status and work productivity in the United States: results from living with MPN patient survey; 2016 Jan. (Blood; vol. 128). Rampal RK, Tamari R. Zhang N, McNamara CJ, Rapaport F, Litvin R, Maloy MA, Castro-Malaspina H, Giralt S, Weinberg RS, Mascarenhas J, Mesa RA, Rondelli D, Dueck AC, Levine RL, Gupta V, Hoffman R. Impact of genomic alterations on outcomes in myelofibrosis patients undergoing allogeneic hematopoietic stem cell transplantation; 2016 Jan. (Blood; vol. 128). Gupta V, Kosiorek HE, Klisovic RB, Galvin JP, Berenzon D, Yacoub A, Mesa RA, Tognoni G, Prosperini G, DiLelio A, Serone E, Marfisi L, Orellano A, Potiphar L, Salama ME, Weinberg RS, Dueck AC. Exploring the potential of JAK1/2 inhibitor ruxolitinib with reduced intensity hematopoietic cell transplantation (HCT) for myelofibrosis: stage I results of a prospective trial conducted through the myeloproliferative disorders - research consortium (MP; 2016 Jan. (Blood; vol. 128). Stein BL, Naim A, Grunwald MR, Moliterno AR, Oh ST, Paranagama D, Codaro JA, Sun H, Parasuraman S, Boccia RV, Mesa R. Examining the clinical features and underlying cardiovascular risk among patients with polycythemia vera in the REVEAL study; 2016 Jan. (Blood; vol. 128). Padrnos L, Bennett R, Kosiorek HE, Mikhael J, Dueck AC, Northfelt DW, Tibes R, Khera N, Mesa RA. Differences in cancer education between patients with hematologic malignancies and solid tumor malignancies: Lessons from a large multi-disease patient education symposium; 2016 Jan. (Blood; vol. 128). Jain T, Temkit M, Partain DK, Patnaik MM, Slack JL, Khera N, Hogan WJ, Roy V, Noel P, Leis JF, Sproat L, Fauble VDS, Mesa RA, Palmer J. Day 30 and day 100 CD33 chimerisms predict survival after allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis; 2016 Jan. (Blood; vol. 128). Harrison CN, Mead A, Fox S, Panchal A, Yap C, Houlton AE, Aliman S, Ewing JC, Wood M, Chen F, Coppell J, Panoskaltsis N, Knapper S, Ali S, Hamblin A, Scherber RM, Geyer H, Scotch AH, Dueck AC, Cross NCP, Mesa RA, McMullin MF. Correlation between treatment outcomes, baseline characteristics and molecular responses in the Majic study which compared ruxolitinib to best available therapy in essential thrombocythemia; 2016 Jan. (Blood; vol. 128). Scherber RM, Geyer H, Kosiorek HE, Dueck AC, Kiladjian J-J, Slot S, Zweegman S, Boekhorst PT, Commandeur Z, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernandez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn J-Y, Harrison CN, Radia D, Muxi PJ, Maldonado NI, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari M, Rambaldi A, Samuelsson J, Cannon K, Sun X, Xu J, Zhang P, Xu Z, Mesa RA. Consideration of symptom burden based treatment in PV and ET patients: an analysis by MPN international quality of life study group; 2016 Jan. (Blood; vol. 128). Whatcott CJ, Bogenberger JM, Kim W, Haws H, Hansen N, Delman D, Sproat L, Palmer J, Mesa RA, Peterson P, Siddiqui-Jain A, Weitman S, Bearss DJ, Warner SL, Tibes R. Alvocidib potentiates the activity of venetoclax in preclinical models of acute myeloid leukemia; 2016 Jan. (Blood; vol. 128). Finazzi G, Martino B, Pezzuto A, Hellmann A, McMullin MF, Noble R, von Bubnoff N, Cambier N, Marolleau J-P, Ruggeri M, Vannucchi AM, Mesa R, Tibes R, Bettica P, Tollo SDI, Rambaldi A. A two-part study of givinostat in patients with polycythemia vera: Maximum tolerated dose definition and preliminary efficacy results; 2016 Jan. (Blood; vol. 128). Menghrajani K, Boonstra PS, Perkins C, Gowin KL, Mesa RA, Gotlib JR, Talpaz M. A predictive model for response in myelofibrosis patients treated with JAK2 inhibitors: A study from three US academic centers and a large industry-based cohort; 2016 Jan. (Blood; vol. 128). Verstovsek S, Talpaz M, Ritchie E, Wadleigh M, Odenike O, Jamieson C, Stein B, Uno T, Mesa RA. A phase 1/2 study of ns-018, an oral jak2 inhibitor, in patients with primary myelofibrosis (pmf), post-polycythemia vera myelofibrosis (ppv mf), or post-essential thrombocythemia myelofibrosis (pet mf); 2015 Dec. (Blood; vol. 126, no. 23). Geyer H, Scherber RM, Kosiorek H, Dueck AC, Kiladjian JJ, Slot S, Xiao ZJ, Zweegman S, Sackmann F, Fuentes AK, Hernandez-Maraver D, Dohner K, Harrison CN, Radia D, Muxi PJ, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Maldonado NI, Barosi G, Ferrari M, Gale RP, Birgegard G, Xu ZF, Zhang Y, Sun XJ, Xu JQ, Zhang PH, Te Boekhorst PA, Commandeur S, Schouten HC, Pahl HL, Griesshammer M, Stegelmann F, Lehmann T, Vannucchi AM, Passamonti F, Samuelsson J, Mesa RA. Unmet needs for symptom control in essential thrombocythemia with front line therapy; 2015 Dec. (Blood; vol. 126, no. 23). Partain DK, Damlaj M, Al -Kali A, Gangat N, Litzow MR, Hogan WJ, Hashmi SK, Gonsalves WI, Foran JM, Roy V, Mesa RA, Palmer J, Slack JL, Patnaik MM. The role of spleen directed therapy and predictors of outcomes with reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for patients with primary myelofibrosis and splenomegaly; 2015 Dec. (Blood; vol. 126, no. 23). Geyer H, Scherber RM, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao ZJ, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernandez-Maraver D, Dohner K, Harrison CN, Radia D, Muxi PJ, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Maldonado NI, Barosi G, Ferrari M, Gale RP, Birgegard G, Xu ZF, Zhang Y, Sun XJ, Xu JQ, Zhang PH, te Boekhorst P, Commandeur S, Schouten HC, Pahl HL, Griesshammer M, Stegelmann F, Lehmann T, Vannucchi AM, Passamonti F, Samuelsson J, Mesa RA. Symptom burden profile in myelofibrosis patients with thrombocytopenia: lessons and unmet needs; 2015 Dec. (Blood; vol. 126, no. 23). Mesa RA, Boccia RV, Moliterno A, Naim AB, Cordaro JA, Peng W, Sun H, Parasuraman SV, Stein B. Self-reported quality-of-life impairment and productivity loss in patients with polycythemia vera: early patient-reported outcomes assessment from the reveal study; 2015 Dec. (Blood; vol. 126, no. 23). Mesa RA, Harrison CN, Cervantes F, Dean JP, Wang LX, Granston T, Yang Y, Vannucchi AM, Mead A. Relationship between patient-reported outcomes (pros) and health-related quality of life (hrqol) and efficacy in patients with myelofibrosis in the phase iii persist-1 trial of pacritinib vs. best available therapy (bat); 2015 Dec. (Blood; vol. 126, no. 23). Verstovsek S, Mesa RA, Foltz LM, Gupta V, Mascarenhas JO, Ritchie EK, Hoffman R, Silver RT, Kremyanskaya M, Pozdnyakova O, Hasserjian RP, Trehu E, Salama ME, Kantarjian HM, Gotlib J. Prm-151 in myelofibrosis: durable efficacy and safety at 72 weeks; 2015 Dec. (Blood; vol. 126, no. 23). Coakley M, Gowin KL, Kosiorek HE, Mesa RA. Poor correlation between dipss and passamonti prognostic risk scores for post polycythemia vera and essential thrombocythemia myelofibrosis; 2015 Dec. (Blood; vol. 126, no. 23). Fazal S, Miller CB, Mascarenhas JO, Thyne M, Goldberger S, Paranagama DC, Parasuraman SV, Naim AB, Mangan J, Mesa RA. Phlebotomy frequency and quality of life and productivity in patients with polycythemia vera: results from the mpn landmark survey in the United States; 2015 Dec. (Blood; vol. 126, no. 23). Gowin KL, Jain T, Kosiorek HE, Camoriano J, Tibes R, Palmer J, Mesa RA. Pegylated interferon alpha-2a in 75 patients with myeloproliferative neoplasms: a single center experience; 2015 Dec. (Blood; vol. 126, no. 23). McMullin MF, Duncombe A, Titmarsh GJ, de Vocht F, Fritschi L, Mesa RA, Clarke M, Anderson LA. Myeloproliferative neoplasms: an in-depth case-control (mosaicc) study; 2015 Dec. (Blood; vol. 126, no. 23). Anderson LA, Titmarsh GJ, Dueck AC, Duncombe A, Mesa RA, Scherber RM, Kosiorek HE, de Vocht F, Clarke M, McMullin MF. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls using multivariate analysis; 2015 Dec. (Blood; vol. 126, no. 23). Padrnos L, Mikhael J, Bennett R, Kosiorek H, Dueck AC, Northfelt DW, Tibes R, Khera N, Mesa RA. Living with cancer: an educational intervention in cancer patients can improve knowledge deficit; 2015 Dec. (Blood; vol. 126, no. 23). Scherber RM, Geyer H, Harrison CN, Kosiorek HE, Dueck AC, Kiladjian JJ, Slot S, Xiao ZJ, Zweegman S, Sackmann F, Fuentes AK, Hernandez-Maraver D, Dohner K, Radia D, Muxi PJ, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy J, Cahn JY, Maldonado NI, Barosi G, Ferrari M, Gale RP, Birgegard G, Xu ZF, Zhang Y, Sun XJ, Xu JQ, Zhang PH, te Boekhorst PA, Commandeur S, Schouten HC, Pahl HL, Griesshammer M, Stegelmann F, Lehmann T, Vannucchi AM, Passamonti F, Samuelsson J, Mesa RA. Impact of disease duration upon symptom burden amongst patients with myeloproliferative neoplasms (mpns); 2015 Dec. (Blood; vol. 126, no. 23). Bogenberger JM, Hansen N, Delman D, Mesa RA, Tibes R. Identification and mechanistic characterization of cmpd1 as a selective sensitizer of histone deacetylase inhibitors in myeloid malignancies; 2015 Dec. (Blood; vol. 126, no. 23). Mesa RA, Miller CB, Mascarenhas JO, Thyne M, Goldberger S, Paranagama DC, Parasuraman SV, Fazal S, Naim AB, Mangan J. Hydroxyurea treatment history and quality of life in patients with polycythemia vera: results from the mpn landmark survey in the United States; 2015 Dec. (Blood; vol. 126, no. 23). Parasuraman SV, Naim AB, Paranagama DC, Thyne M, Goldberger S, Mascarenhas JO, Mangan J, Fazal S, Miller CB, Mesa RA. Financial burden of myeloproliferative neoplasms on patients: results from the mpn landmark survey in the United States; 2015 Dec. (Blood; vol. 126, no. 23). Gowin KL, Kosiorek HE, Dueck AC, Mascarenhas J, Hoffman R, Reeder CB, Camoriano J, Fauble V, Tibes R, Gano K, Ghurye V, Koenig P, Mesa RA. Final analysis of a multicenter pilot phase 2 study of ruxolitinib and danazol in patients with myelofibrosis; 2015 Dec. (Blood; vol. 126, no. 23). Stein B, Moliterno A, Boccia RV, Naim AB, Cordaro JA, Peng W, Sun H, Parasuraman SV. Disease and clinical characteristics of patients with polycythemia vera: an early view of the reveal study; 2015 Dec. (Blood; vol. 126, no. 23). Gupta V, Mesa RA, Deininger MW, Rivera CE, Sirhan S, Verstovsek S, Zhang YF, Xiao YY, Collins H, Kwei K, Joshi A, Brachmann CB. Circulating cytokines and markers of iron metabolism in myelofibrosis patients treated with momelotininb: correlatives from the ym-387-ii study; 2015 Dec. (Blood; vol. 126, no. 23). Boccia RV, Stein B, Mesa RA, Naim AB, Cordaro JA, Peng W, Sun H, Parasurama SV, Moliterno A. Burden of phlebotomy in patients with polycythemia vera in the United States: baseline data from the reveal study; 2015 Dec. (Blood; vol. 126, no. 23). Scherber RM, Knapper S, Fox S, Kosiorek HE, Shah M, Abdi-Moradi S, Mead AJ, Dueck AC, Ailman S, Green AR, Wood M, Ewing J, Chen F, Coppell J, McMullin MF, Geyer H, Mesa RA, Harrison CN. Assessment and validation of the eq-5d among a population of myeloproliferative neoplasm patients; 2015 Dec. (Blood; vol. 126, no. 23). Vannucchi AM, Mesa RA, Cervantes F, Prasad R, Jakucs J, Elinder A, Mdphd CR, te Boekhorst PA, Knapper S, Somervaille T, Dean JP, Granston T, Mead A, Harrison CN. Analysis of outcomes by patient subgroups in patients with myelofibrosis treated with pacritinib vs best available therapy (bat) in the phase iii persist-1 trial; 2015 Dec. (Blood; vol. 126, no. 23). Verstovsek S, Savona MR, Mesa RA, Oh S, Dong H, Thai D, Gotlib J. A phase 2 study to evaluate the efficacy and safety of simtuzumab in adult subjects with primary, post polycythemia vera (pv) or post essential thrombocythemia (et) myelofibrosis; 2015 Dec. (Blood; vol. 126, no. 23). Vannucchi AM1, Kantarjian HM2, Kiladjian JJ3, Gotlib J4, Cervantes F5, Mesa RA6, Sarlis NJ7, Peng W7, Sandor V7, Gopalakrishna P8, Hmissi A8, Stalbovskaya V8, Gupta V9, Harrison C10, Verstovsek S2; COMFORT Investigators. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. doi: 10.3324/haematol.2014.119545. Epub 2015 Jun 11; 2015 Sep. (Haematologica; vol. 100, no. 9). Trehu E, Pozdnyakova O, Hasserjian R, Salama M, Mesa R, Foltz L, Gupta V, Mascarenhas J, Ritchie E, Hoffman R, Silver R, Kremyanskaya M, Kantarjian H, Gotlib J, Verstovsek S. Bone marrow fibrosis by who grade and quantitative image analysis is reduced by prm-151 in patients with myelofibrosis and associated with improved bone marrow morphology and increased platelet counts; 2015 Jun. (Haematologica; vol. 100). Menghrajani K, Boonstra PS, Weber A, Perkins C, Gowin K, Nguyen H, Mesa R, Gotlib JR, Talpaz M. To treat or not to treat: a novel stratification of myelofibrosis patients by likelihood of response to jak2 inhibitors; 2015 Jun. (Clinical Lymphoma Myeloma; vol. 15). Van Laar E, Blevins D, Levine R, Mesa R. Simulation in continuing education: improving hematologist evidence-based decisions for myeloproliferative neoplasm management; 2015 Jun. (Haematologica; vol. 100). Verstovsek S, Mesa R, Martino B, Kiladjian JJ, Jones MM, He S, Habr D, Alecu I, Vannucchi AM. Safety of ruxolitinib in patients with polycythemia vera: results from the clinical trial program; 2015 Jun. (Haematologica; vol. 100). Kiladjian JJ, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Cazzola M, Besses C, Blau I, Mesa R, Jones MM, He S, Zhen H, Li J, Francillard N, Habr D, Verstovsek S. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the response trial; 2015 Jun. (Haematologica; vol. 100). Duncombe A, Titmarsh G, McMullin MF, Mesa R, Scherber R, Dueck A, De Vocht F, Fritschi L, Clarke M, Anderson LA. Quality of life in patients with myeloproliferative neoplasms compared to normal individuals-case-control evidence of significant impairment; 2015 Jun. (Haematologica; vol. 100). Geyer H, Kosiorek H, Scherber R, Dueck A, Jean-Jacques K, Xiao Z, Zweegman S, Sackman F, Hernandez-Maraver D, Dohner K, Harrison C, Radia D, Muxi P, Besses C, Cervantes F, Johansson P, Andreasson B, Rambaldi A, Barbui T, Vannucchi A, Passamonti F, Samuelsson J, Birgegard G, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Maldonado N, Barosi G, Ferrari M, Cannon K, te Boekhorst PAW, Klauke K, Schouten H, Pahl H, Griesshammer M, Stegelmann F, Lehmann T, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, Mesa R. Primary myelofibrosis, post-et and post-pv myelofibrosis have distinct clinical profiles and symptomatic burdens: an analysis by the mpn quality of life international study group (mpn-qol isg); 2015 Jun. (Haematologica; vol. 100). Uno T, Verstovsek S, Mesa R, Talpaz M, Ritchie E, Wadleigh M, Odenike OM, Jamieson C, Stein B. Phase 1/2, dose-escalation study of oral ns-018 in patients with primary myelofibrosis (pmf), post-polycythemia vera mf (post-pv mf), or post-essential thrombocythemia mf (post-et mf); 2015 Jun. (Haematologica; vol. 100). Harrison C, Szoke A, Suvorov A, Egyed M, Prasad R, Mayer J, Jakucs J, Elinder A, Recher C, te Boekhorst PA, Knapper S, Somervaille T, Ciceri F, Quddus F, Straetmans N, Niederwieser D, Dean JP, Granston T, Kiladjian JJ, Vannucchi A, Nangalia J, Mead A, Mesa R. Persist-1: a phase iii study of pacritinib (pac) vs best available therapy (bat) in primary myelofibrosis (pmf), post-polycythemia vera mf (ppv-mf) or post-essential thrombocythemia mf (pet-mf); 2015 Jun. (Haematologica; vol. 100). Mesa R, Vannucchi A, Mead A, Wang L, Yang Y, Harrison C. Patient-reported outcomes (pros) in persist-1: a randomized, multi-country phase iii trial of the jak2 inhibitor pacritinib (pac) vs. best available therapy (bat) in myelofibrosis (mf); 2015 Jun. (Haematologica; vol. 100). Scherber R, Zhenya S, Geyer H, Dueck A, Clark M, Goldstein M, Kosiorek H, Boxer M, McCallister A, Cotter M, VanHusen B, Harrison C, Mesa R. Patient self-care interventions: do they impact mpn- related fatigue?; 2015 Jun. (Haematologica; vol. 100). Anderson L, Titmarsh G, McMullin MF, Duncombe A, Mesa R, Scherber R, Dueck A, DeVocht F, Fritschi L, Clarke M. Myeloproliferative neoplasm patients experience significant symptom burden; 2015 Jun. (Eur J Cancer Care; vol. 24). Padrnos L, Bennett R, Wu Q, Northfelt D, Mikhael J, Tibes R, Nagi Reddy S, Khera N, Mesa R. Knowledge assessment and educational intervention at a patient centered cancer symposium; 2015 Jun. (Haematologica; vol. 100). Gowin K, Dueck A, Mascarenhas J, Hoffman R, Reddy SN, Reeder C, Camoriano J, Fauble V, Tibes R, Gano K, Ghurye V, Koenig P, Mesa R. Interim analysis of a phase ii pilot trial of ruxolitinib combined with danazol for patients with myelofibrosis suffering from anemia; 2015 Jun. (Haematologica; vol. 100). Gowin KL, Verstovsek S, Daver NG, Pemmaraju N, Valdez R, Kosiorek H, Dueck AC, Mesa RA. Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis; 2015 May. (Clin Oncol; vol. 33, no. 15). Verstovsek S, Mesa RA, Martino B, Kiladjian JJ, Jones MM, He S, Habr D, Alecu I, Vannucchi AM. Ruxolitinib safety experience in the polycythemia vera clinical trial program; 2015 May. (J Clin Oncol; vol. 33, no. 15). Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Hino M, Moiraghi B, Miller CB, Rosti V, Mesa RA, Jones MM, Zhen HL, Li JJ, Francillard N, Habr D, Kiladjian JJ. Ruxolitinib in polycythemia vera: follow-up from the response trial; 2015 May. (J Clin Oncol; vol. 33, no. 15). Mesa RA, Egyed M, Szoke A, Suvorov A, Perkins A, Mayer J, Ganly P, Jourdan E, Schouten HC, Tosi P, Farber CM, Zachee P, Scheid C, Dean JP, Cernohous P, Nangalia J, Kiladjian JJ, Vannucchi AM, Mead A, Harrison CN. Results of the persist-1 phase iii study of pacritinib (pac) versus best available therapy (bat) in primary myelofibrosis (pmf), post-polycythemia vera myelofibrosis (ppv-mf), or post-essential thrombocythemia-myelofibrosis (pet-mf); 2015 May. (J Clin Oncol; vol. 33, no. 15). Scherber R, McMullin MF, Mead A, Fox S, Shah M, Abdi-Moradi S, Bell H, Doueck A, Aliman S, Green A, Wood M, Ewing J, Chen F, Coppell J, Knapper S, Yap C, Ahmed I, Geyer H, Mesa R, Harrison C. Baseline quality of life and symptom burden characteristics of patients intolerant to hydroxyurea: preliminary results from the majic trial; 2015 Apr. (Br J Haematol; vol. 169). Fauble V, Noel P, Mesa RA, Adams R, Leis J, Khera N, Sproat LO, Palmer J, Betcher J, Slack JL. Ruxolitinib prior to allogeneic stem cell transplant: the experience at Mayo Clinic Arizona; 2015 Feb. (Biol Blood Marrow Transplant; vol. 21, no. 2). Tibes R, Kosiorek HE, Dueck AC, Sproat L, Palmer J, Slack JL, Singh D, Gebhart E, Knight E, Hashmi SK, Wilcox RA, Bogenberger JM, Mesa RA, Al-Kali A. Phase I/IB Study of Azacitidine and Hedgehog Pathway Inhibition in Myeloid Malignancies; 2015 Jan. (Blood; vol. 126). Wehrle, J; Geer, T; Brudler, O; Schaefer, E; Tesch, H; Cavanna, D; Bachhuber, P; Markhauser, M; Koschmieder, S; Mesa, R A; Pahl, H L. Interim results of the phase IV JAKoMo trial, a prospective, non-interventional study of symptoms and quality of life in myelofibrosis patients receiving ruxolitinib therapy; 2015 Jan. (Oncology Research and Treatment; vol. 38, no. Sppl5). Kamal M, Boonstra PS, Weber AA, Perkins C, Gowin KL, Nguyen H, Mesa R, Gotlib JR, Talpaz M. A new prognostic model for response in myelofibrosis patients treated with jak2 inhibitors: a study from three US academic centers; 2014 Dec. (Blood; vol. 124, no. 21). Padrnos LJ, Wu Q, Scherber RM, Northfelt DW, Mikhael JR, Bennett RM, Dueck AC, Mesa R. Understanding and information in cancer patients: the impact of a cancer symposia on patient knowledge; 2014 Dec. (Blood; vol. 124, no. 21). Scherber RM, Senyak Z, Dueck AC, Clark M, Boxer M, McCallister A, Cotter M, VanHusen B, Harrison CN, Mesa R. The impact of medical comorbidities in mpn-related fatigue; 2014 Dec. (Blood; vol. 124, no. 21). Tibes R, Delman D, Hansen N, Gowin KL, Mesa R, Bogenberger JM. The hedgehog pathway as targetable vulnerability with 5-azacitidine in mds and aml; 2014 Dec. (Blood; vol. 124, no. 21). Mesa R, Vannucchi AM, Yacoub A, Zachee P, Garg M, Lyons R, Chedid S, Koschmieder S, Rinaldi C, Byrne J, Hasan Y, Passamonti F, Verstovsek S, Hunter D, Jones MM, He S, Morozov A, Martino B. The efficacy and safety of continued hydroxyurea therapy versus switching to ruxolitinib in patients with polycythemia vera: a randomized, double-blind, double-dummy, symptom study (relief); 2014 Dec. (Blood; vol. 124, no. 21). Gowin KL, Dueck AC, Verstovsek S, Daver N, Pemmaraju N, Valdez R, Mesa RA. The clinical phenotype of patients with primary myelofibrosis, polycythemia vera, and essential thrombocytosis whom only manifest who grade 1 fibrosis; 2014 Dec. (Blood; vol. 124, no. 21). Geyer HL, Scherber RM, Dueck AC, Kiladjian JJ, Xiao ZJ, Slot S, Zweegman S, Fuentes AK, Hernandez-Maraver D, Dohner K, Harrison CN, Radia DH, Muxi PJ, Sackman F, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Vannucchi AM, Passamonti F, Samuelsson J, Birgegard G, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Maldonado NI, Barosi G, Ferrari M, Cannon K, te Boekhorst P, Schouten HC, Pahl HL, Griesshammer M, Stegelmann F, Lehmann T, Xu ZF, Zhang Y, Sun XJ, Xu JQ, Zhang PH, Mesa R. Symptom severity and clinical variables of polycythemia vera patients with splenomegaly, phlebotomy requirements and/or hydroxyurea use: a retrospective evaluation of 1334 patients; 2014 Dec. (Blood; vol. 124, no. 21). Verstovsek S, Kiladjian JJ, Mesa R, Jones MM, He S, Li JJ, Habr D, Vannucchi AM. Ruxolitinib efficacy by hematocrit control in patients with polycythemia vera: an analysis of the response trial; 2014 Dec. (Blood; vol. 124, no. 21). Miller CB, Komrokji RS, Mesa R, Sun W, Montgomery M, Verstovsek S. Practical measures of clinical benefit with ruxolitinib therapy: an exploratory analysis of comfort-i; 2014 Dec. (Blood; vol. 124, no. 21). Verstovsek S, Mesa RA, Foltz LM, Gupta V, Mascarenhas JO, Ritchie EK, Hoffman R, Silver RT, Kremyanskaya M, Pozdnyakova O, Hasserjian RP, Trehu E, Kantarjian HM, Gotlib JR. Phase 2 trial of prm-151, an anti-fibrotic agent, in patients with myelofibrosis: stage 1 results; 2014 Dec. (Blood; vol. 124, no. 21). Bogenberger JM, Hansen N, Delman D, Mesa RA, Tibes R. Mk2a substrate-selective p38 inhibitor cmpd1 selectively synergizes with hdac inhibitors in cd34( ) cells from myeloid malignancies; 2014 Dec. (Blood; vol. 124, no. 21). Gowin KL, Dueck AC, Mascarenhas JO, Hoffman R, Reeder CB, Camoriano J, Gano K, Ghurye V, Reddy SN, Koenig P, Fauble V, Tibes R, Mesa R. Interim analysis of a phase ii pilot trial of ruxolitinib combined with danazol for patients with primary myelofibrosis (mf), post essential thrombocythemia-myelofibrosis (post et), and post polycythemia vera myelofibrosis (pv mf) suffering from anemia; 2014 Dec. (Blood; vol. 124, no. 21). Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma XM, Wilson W, Dubinski DG, Boyle J, Mascarenhas JO. Impact of myeloproliferative neoplasms (mpns) on patients' overall health and productivity: results from the mpn landmark survey in the United States; 2014 Dec. (Blood; vol. 124, no. 21). Scherber RM, Senyak Z, Dueck AC, Clark M, Boxer M, McCallister A, Cotter M, VanHusen B, Harrison CN, Mesa R. High prevalence of mood disorders in mpns and their possible role in mpn related fatigue; 2014 Dec. (Blood; vol. 124, no. 21). Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma XM, Wilson W, Dubinski DG, Boyle J, Mascarenhas JO. Gaps in perception between patients and physicians regarding symptomatology and treatment attitudes for myeloproliferative neoplasms: mpn landmark survey; 2014 Dec. (Blood; vol. 124, no. 21). Singer J, Al-Fayoumi S, Ma HC, Komrokji RS, Mesa R, Verstovsek S. Comprehensive kinase profile of pacritinib, a non-myelosuppressive jak2 kinase inhibitor in phase 3 development in primary and post et/pv myelofibrosis; 2014 Dec. (Blood; vol. 124, no. 21). Kiladjian JJ, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, Jones MM, He S, Li JJ, Habr D, Verstovsek S. Clinical benefit of ruxolitinib treatment after crossover from best available therapy in patients with polycythemia vera: analysis of the response trial; 2014 Dec. (Blood; vol. 124, no. 221). Mesa R, Verstovsek S, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, He S, Jones MM, Parasuraman S, Li JJ, Cote I, Habr D, Vannucchi AM. Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or best available therapy: response trial results; 2014 Dec. (Blood; vol. 124, no. 21). Verstovsek S, Talpaz M, Ritchie EK, Wadleigh M, Odenike O, Jamieson C, Stein BL, Tomonori U, Mesa R. A phase 1/2, open-label, dose-escalation, multi-center study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered ns-018 in patients with primary myelofibrosis (pmf), post-polycythemia vera myelofibrosis (post; 2014 Dec. (Blood; vol. 124, no. 21). Tibes R, Delman D, Hansen N, Gowin KL, Mesa R, Bogenberger JM. The hedgehog pathway as a targetable vulnerability with 5-azacitidine in MDS and AML; 2014 Nov. (Blood). Tibes R, Chaudhuri L, Vincelette ND, Kohl BD, Naylor RM, Flatten KS, Peterson KL, McNally A, Gojo I, Karp JE, Mesa RA, Sproat LO, Bogenberger JM, Kaufmann SH. Chk1 and wee1 inhibition combine synergistically and represent a novel non-cytotoxic combination in acute myeloid leukemia; 2014 Sep. (Clin Lymphoma Myeloma Leuk; vol. 14). Gupta V, Mesa R, Deininger M, Rivera C, Sirhan S, Kawashima J, Shao L, Collins H, Verstovsek S. A phase i/ii, open-label study evaluating twice-daily administration of momelotinib (gs-0387, cyt387) in primary myelofibrosis or post-polycythemia vera or post-essential thrombocythemia myelofibrosis; 2014 Jun. (Haematologica; vol. 99). Verstovsek S, Kiladjian J-J, Griesshammer M, Masszi T, Durrant STS, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa RA, He S, Jones M, Garrett WM, Li J, Pirron U, Lawniczek T, Vannucchi AM. Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial; 2014 Jun. (J Clin Oncol; vol. 11). Verstovsek S, Mesa RA, Foltz LM, Gupta V, Mascarenhas J, Ritchie EK, Hoffman R, Silver RT, Hong W-J, Kremyanskaya M, Trehu EG, Kantarjian HM, Gotlib JR. Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results; 2014 Jun. (J Clin Oncol; vol. 11). Sasaki K, Gotlib JR, Mesa RA, Ravandi F, Cortes JE, Kelly PF, Kutok JL, Kantarjian HM, Verstovsek S. A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis; 2014 Jun. (J Clin Oncol; vol. 11). Scherber R, Senyak Z, Dueck A, Clark M, Goldstein M, Boxer M, McCallister A, Cotter M, Harrison C, Mesa RA. The mpn fatigue project stage 2: understanding the role of comorbid conditions and fatigue-alleviating strategies in mpn fatigue; 2014 Jun. (Haematologica; vol. 99). Geyer H, Emanuel R, Dueck A, Alchaby H, Michaelis L, Kroger N, Giralt S, Guptas V, Popat U, Mesa R, Fauble V. Symptoms trial update: symptoms yielded in myelofibrosis patients after transplant as objectified by the mpn-saf tss; 2014 Jun. (Haematologica; vol. 99). Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Francillard N, Habr D, Verstovsek S. Ruxolitinib proves superior to best available therapy in a prospective, randomized, phase 3 study (response) in patients with polycythemia vera resistant to or intolerant of hydroxyurea; 2014 Jun. (Haematologica; vol. 99). Begna K, Animesh P, Litzow M, Hanson C, Mesa R, Hogan W, Tefferi A. Pomalidomide in myelofibrosis: long term follow up and correlation with jak2v617f and calr mutations; 2014 Jun. (Haematologica; vol. 99). Verstovsek S, Mesa R, Foltz L, Gupta V, Mascarenhas J, Ritchie E, Hoffman R, Silver R, Hong WJ, Kremyanskaya M, Trehu E, Kantarjian H, Gotlib J. Phase 2 trial of prm-151, an anti-fibrotic agent, in patients with myelofibrosis: stage 1 results; 2014 Jun. (Haematologica; vol. 99). Geyer H, Emanuel R, Dueck A, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackman F, Fuentes AK, Hernandez-Maraver D, Dohner K, Harrison C, Radia D, Muxi P, Besses C, Cervantes F, Johansson P, Andreasson B, Rambaldi A, Barbui T, Vannucchi A, Passamonti F, Samuelsson J, Birgegard G, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Maldonado N, Barosi G, Ferrari M, Cannon K, te Boekhorst PA, Klauke K, Schouten H, Pahl H, Griesshammer M, Stegelmann F, Lehmann T, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, Mesa R. Gender differences and mpn symptom burden: an analysis by the mpn quality of life international study group (mpn-qol isg); 2014 Jun. (Haematologica; vol. 99). Padrnos L, Wu Q, Scherber R, Robert B, Amylou D, Mesa R. Educational intervention in cancer patients: the impact of a cancer symposia on patient knowledge; 2014 Jun. (Haematologica; vol. 99). Scherber R, Dueck A, Knight E, Ross D, Geyer H, Vannucchi A, Fuentes AK, Andersen CL, Ejerblad E, Birgegard G, Johansson P, Andreasson B, Sackmann F, Demory JL, Constantine T, Michiels JJ, Radia D, Harrison C, Tefferi A, Mesa RA. An international assessment of standard medical therapy on symptom burden among mpn populations: preliminary findings of the measure trial; 2014 Jun. (Haematologica; vol. 99). Gowin K, Cherington C, Slack J, Tibes R, Sproat L, Mesa R. Allogeneic transplant outcomes in mpn blast phase; 2014 Jun. (Haematologica; vol. 99). Vekeman F, Huynh L, Sasane M, Cheng W, Duh MS, Paley C, Mesa R. Medical complications and resource utilization in blood transfusion-dependent patients with myelofibrosis by iron chelation therapy use; 2014 May. (Value Health; vol. 17, no. 3). Altriki M, Cheng MR, Fauble V, Khera N, Leis J, Mesa RA, Noel P, Slack JL, Tibes R, Sproat LO. Central nervous system leukemia in acute myeloid leukemia; 2014 Feb. (Biol Blood Marrow Transplant; vol. 20, no. 2). Dueck AC, Cleeland CS, Dantzer R, Sloan J, Verstovsek S, Emanuel RM, Geyer HL, Mesa RA. Cytokine Profile Changes in 309 Myelofibrosis Patients: Comparison of JAK1/JAK2 Inhibitor Therapy vs Placebo - Correlative Analysis from the COMFORT-I Trial. Abstract no. 14866; 2013 Nov. (Blood; vol. 122, no. 21). Hagop K, Kiladjian J-J, Gotlib J, Cervantes F, Mesa RA, Barosi G, Sarlis N, Peng W, Sandor VA, Sirulnik A, Hmissi A, Stalbovskaya V, Gupta V, Harrison CN, Verstovsek S. A Pooled Overall Survival Analysis of the COMFORT Studies: 2 Randomized Phase 3 Trials of Ruxolitinib for the Treatment of Myelofibrosis. ASH Abstract 14869; 2013 Oct. (Blood; vol. 122, no. 21). Senyak Z, McCallister A, Cotter M, VanHusen B, Harrison CN, Mesa RA. The MPN Fatigue Project: Stage 1 Results of the MPN Forum Internet-Based Survey Among 879 MPN Patients. ASH Abstract 14881; 2013 Oct. (Blood; vol. 122, no. 21). Mesa R, Cortes JE, Cervantes F, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond M, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Joulain F, Iqbal SU, Harrison CN. Symptom Burden and Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis (MF) Treated with Fedratinib (SAR302503) in a Phase III Study (JAKARTA). ASH Abstract 14865; 2013 Oct. (Blood; vol. 122, no. 21). Dueck, AC, Emanuel RM, Cannon K, Kiladjian J-J, Slot S, Zweegman S, Boekhorst P, Commandeur S, Schouten HC, Sackmann F, Fuentes AK, Hernandez D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Ranta D, Reiter A, Boyer F, Etienne G, Ianotto J-C, Roy L, Cahn J-Y, Harrison CN, Radia DH, Muxi PJ, Maldonado NI, Besses C, Cervantes F, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari M, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Sun X, Xu J, Zhang P, Gale RPeter, Mesa RA. Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). ASH Abstract 14876; 2013 Oct. (Blood; vol. 122, no. 21). Harrison CN, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond M, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Gao G, Tefferi A. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) of The JAK2-Selective Inhibitor Fedratinib (SAR302503) in Patients with Myelofibrosis (MF). ASH Abstract 14871; 2013 Oct. (Blood; vol. 122, no. 21). Mesa RA, Noel P, Adams R, Chang Y, Leis JF, Khera N, Sproat L, Reeder C, Klein J, Betcher JA, Higgins M, DeCook L, Palmer J, Gerber S, Henderson K, Beebe K, Chiffelle R, Olsen J, Toro A, Slack JL. Reduced Toxicity Conditioning with Fludarabine, BCNU, Melphalan and Anti-Thymocyte Globulin followed by Allogeneic Stem Cell Transplant for Patients with Primary and Post ET/PV Myelofibrosis: Single Center Experience at Mayo Clinic Arizona. ASH Abstract; 2013 Oct. (Blood; vol. 122, no. 21). Mesa RA, Salama ME, Giles JLK, Pitou C, Zimmermann AH, Price GL, Walgreen RA, Prchal J. Phase I Study of LY2784544, a JAK2 Selective Inhibitor, in Patients with Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET). ASH Abstract 14875; 2013 Oct. (Blood; vol. 122, no. 21). Passamonti F, Barbui T, Barosi G, Begna K, Cazzola M, Cervantes F, Döhner K, Gisslinger H, Gupta V, Li W, Harrison CN, Kiladjian J-J, McMullin MF, Rambaldi A, Schiller GJ, Vannucchi AM, Mesa RA. Phase I Study of LY2784544, a JAK2 Selective Inhibitor, in Patients with Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET). ASH Abstract 14875; 2013 Oct. (Blood; vol. 122, no. 21). Passamonti F, Barbui T, Barosi G, Begna K, Cazzola M, Cervantes F, Döhner K, Gisslinger H, Gupta V, Li W, Harrison CN, Kiladjian J-J, McMullin MF, Rambaldi A, Schiller GJ, Vannucchi AM, Mesa RA. Phase 3 Study of Pomalidomide in Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis with RBC-Transfusion-Dependence. ASH Abstract 14874; 2013 Oct. (Blood; vol. 122, no. 21). Rudd J, Chow D, Kassner M, Fauble V, Mesa RA, Yin H, Greene C, Tibes R. Pharmacological Validation of Potentiating Targets from SAHA RNA-Interference Modifier Screens in Acute Myeloid Leukemia. ASH Abstract 14883; 2013 Oct. (Blood; vol. 122, no. 21). Dean JP, Cernohous P, Komrokji RS, Seymour JF, Mesa RA, Campbell MS, Caldwell SE, Wang L, Myint Han. Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis of Phase II Trial Data in Patients with Primary and Secondary Myelofibrosis (MF) and Platelet Counts ≤100,000/?l. ASH Abstract 14870; 2013 Oct. (Blood; vol. 122, no. 21). Mesa R, Komrokji RS, Sun W, Sandor VA, Verstovsek S. Optimizing Dose Titration of Ruxolitinib: the COMFORT-I Experience. ASH Abstract 14864; 2013 Oct. (Blood; vol. 122, no. 21). Emanuel RM, Geyer HL, Dueck AC, Kroeger N, Scott BL, Gerds AT, Popat UR, Giralt SA, Gupta V, Ross D, Knight E, Fuentes AK, Andersen CL, Ejerblad E, Birgegard G, Johansson P, Andreasson B, Sackmann F, Demory J-L, Tam CS, Michiels JJ, Radia DH, Boxer M, Mesa RA. Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Observational Study of Quality of Life and Symptomatic Response in Myelofibrosis Patients Receiving Undergoing Treatment with Conventional Therapy, the Measures Trial and Allogeneic Stem; 2013 Oct. (Blood; vol. 122, no. 21). Dueck AC, Geyer HL, Kiladjian J-J, Slot S, Zweegman S, Boekhorst P te, Commandeur S, Schouten HC, Sackmann F, Hernandez D, Fuentes AK, Pahl HL, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto J-C, Ranta D, Roy L, Cahn J-Y, Harrison CN, Radia DH, Muxi PJ, Maldonado NI, Besses C, Cervantes F, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari M, Griesshammer M, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, Gale RP, Tefferi A, Mesa RA. Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment of MPN-SAF TSS Quartiles as Potential Markers of Symptom Response. ASH Abstract 14880; 2013 Oct. (Blood; vol. 122, no. 21). Vekeman F, Cheng WY, Sasane M, Huynh L, Kaminsky M, Duh MS, Paley C, Mesa R. Medical Complications in Patients with Myelofibrosis by Frequency of Blood Transfusion and Iron Chelation Therapy. ASH Abstract 14867; 2013 Oct. (Blood; vol. 122, no. 21). Verstovsek S, Mesa R, Gotlib J, Levy RS, Gupta V, Dipersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Sun W, Peng W, Sandor VA, Kantarjian HM. Long-Term Outcomes of Ruxolitinib Therapy in Patients with Myelofibrosis: 3-Year Update from COMFORT-I. ASH Abstract 14868; 2013 Oct. (Blood; vol. 122, no. 21). Dueck AC, Bennett RM, Emanuel RM, Mesa RA, Northfelt D, Mikhael JR, Glassley P, Stigge R, Aguirre A. Living with Cancer: Assessing the Educational, Symptomatic, and Quality of Life Impact of a Comprehensive Patient Symposia on Cancer Patients. ASH Abstract 14879; 2013 Oct. (Blood; vol. 122, no. 21). Dueck AC, Emanuel RM, Cannon K, Kiladjian J-J, Slot S, Zweegman S, Boekhorst P, Commandeur S, Schouten HC, Sackmann F, Fuentes AK, Hernandez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Dohner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto J-C, Ranta D, Roy L, Cahn J-Y, Harrison CN, Radia DH, Muxi PJ, Maldonado NI, Besses C, Cervantes F, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari M, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, Peter G, Robert P, Mesa RA. Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG); 2013 Oct. (Blood; vol. 122, no. 21). Schaap NPM, Zweegman S, Jourdan E, Kiladjian J-J, Cervantes F, Niederwieser D, Cortes JE, Passamonti F, Reiter A, Recher C, Döhner K, Heidel FH, Silver RT, Winton EF, Gupta V, Ojeda E, Gisslinger H, Vannucchi AM, Talpaz M, Zhang J, Shi W, Mesa RA. Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). ASH Abstract 14873; 2013 Oct. (Blood; vol. 122, no. 21). Schaap NPM, Zweegman S, Jourdan E, Kiladjian J-J, Cervantes F, Niederwieser D, Cortes JE, Passamonti F, Reiter A, Recher C, Döhner K, Heidel FH, Silver RT, Winton EF, Gupta V, Ojeda E, Gisslinger H, Vannucchi AM, Talpaz M, Zhang J, Shi W, Mesa RA. Efficacy and Safety of Fedratinib (SAR302503/TG101348) in Patients with Intermediate- or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF Previously Treated with Ruxolitinib: Interim Results from a P; 2013 Oct. (Blood; vol. 122, no. 21). Issa J-P, Rizzieri D, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Feldman EJ, Ritchie E, Rao AV, Larson RA, Garcia-Manero G, Ravandi F, Jabbour E, Cortes JE, Schimmer A, Mesa RA, Blum W, Chung W, Naim S, Taverna P, Hao Y, Choy G, Azab M, Kantarjian HM. DNA Demethylation Activity Over Time and Safety of 3 Different Dose-Escalation Regimens of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), in the Treatment of Relapsed/Refractory Patients with MDS and AML; 2013 Oct. (Blood; vol. 122, no. 21). Kornblau SM, Pierceall WE, Lena R, Qiu YH, Cardone M, Chaudhuri L, Fauble V, Elashoff M, Blake N, Mesa RA, Bogenberger JM. BH3 Profiling as Predictor of 5-Azacytidine and Decitabine Clinical Responses. ASH Abstract 14877; 2013 Oct. (Blood). Mehta J, Le-Ruyet O, Fryzek J, Iqbal SU, Mesa R. Epidemiology of primary myelofibrosis (pmf), essential thrombocythemia (et), and polycythemia vera (pv) in the European Union (EU); 2013 Sep. (Eur J Cancer; vol. 49). Yan M, Geyer H, Mesa R, Atallah E, Callum J, Bartoszko J, Wong F, Maganti M, Yee K, Gupta V. Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension (P821); 2013 Jun. (Haematologica; vol. 98, no. s1). Radia DH, Perkins C, Claire HN, Mesa R, Gotlib J. Survey for the validation of modified MPN-symptom assessment form for patients with mast cell disorders (P815); 2013 Jun. (Haematologica; vol. 98, no. s1). Verstovsek S, Liang SY, Komrokji R, Mesa R, Seymour J, Dean JP, Wang L, Singer J, Myint H, Younes A. Safety overview of phase I-II studies of pacritinib, a non-myelosuppressive JAK2/LFT3 inhibitor, in patients with hematological malignancies (P278); 2013 Jun. (Haematologica; vol. 98, no. s1). Geyer H, Emanuel R, Fauble V, Dueck A, Knight E, Vannucchi A, Fuentes A, Andersen C, Ejerblad E, Birgegard G, Johansson P, Andreasson B, Ross D, Sackmann F, Demory JL, Tan C, Michiels JJ, Mesa R. Myeloproliferative neoplasm quality of life (MPN-QOL) study group: dual serial assessment studies for impact of standard therapeutic approaches in MPN populations (measure and symptoms trials) (P273); 2013 Jun. (Haematologica; vol. 98, no. s1). Emanuel R, Marchioli R, Dueck A, Geyer H, Finazzi G, Cavazzina R, Masciulli A, Scarano M, Vannucchi AM, Barbui T, Mesa RA. Impact of hematocrit on symptom burden among polycythemia vera patients (P276); 2013 Jun. (Haematologica; vol. 98, no. s1). Geyer H, Emanuel R, Dueck A, Kiladjian JJ, Slot S, Zweegman S, AW te Boekhorst P, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hernandez-Maraver D, Pahl H, Griesshammer M, Stegelmann F, Dohner K, Lehmann T, Bonatz K, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison C, Radia D, Muxi P, Moldonado N, Besses C, Cervantes F, Johansson P, Barbui T, Barosi G, Vannucchi A, Passamonti F, Andreasson B, Ferrari M, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, Gale R, Mesa R. Do myeloproliferative neoplasms (MPNS) have stages? Analysis of relationship of disease duration prognostic scores, and symptomatic burden of 1467 MPN patients (P266); 2013 Jun. (Haematologica; vol. 98, no. s1).\n\nBook Chapter\n\nMesa R. Myeloproliferative neoplasms: chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, and primary myelofibrosis. In: Tibes R, Mesa RA. Textbook of uncommon cancer. 5th Edition. Raghavan D; et al, editor. 2017. p. 816-829.\n\nEditorial\n\nBogenberger JM, Delman D, Hansen N, Valdez R, Fauble V, Mesa RA, Tibes R. Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Epub 2014 June 17 PMID:24707940 DOI:10.3109/10428194.2014.910657 Leuk Lymphoma 2015 Jan;56(1):226-229. Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe AS, Green AR, Mikhaeel G, Gilleece MH, Knapper S, Mead AJ, Mesa RA, Sekhar M, Harrison CN. Use of jak inhibitors in the management of myelofibrosis: a revision of the british committee for standards in haematology guidelines for investigation and management of myelofibrosis 2012. PMID:24961987 Br J Haematol 2014 Nov;167(3):418-420. Mascarenhas J, Mesa R, Prchal J, Hoffman R. Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials Haematologica 2014 Jun;99(6):945-949. Geyer H, Cannon K, Knight E, Fauble V, Camoriano J, Emanuel R, Tibes R, Mesa R. Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval. Epub 2013 Jun 12 PMID:23647081 DOI:10.3109/10428194.2013.789507 Leuk Lymphoma 2014 Jan;55(1):195-197. Geyer H, Cannon K, Knight E, Fauble V, Camoriano J, Emanuel R, Tibes R, Mesa R. Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval. Epub 2013 Jun 12 PMID:23647081 DOI:10.3109/10428194.2013.789507 Leuk Lymphoma 2014 Jan;55(1):195-197.\n\nElectronic/Web Publication\n\nMesa RA. Myelofibrosis: Trial Results from a Best of ASCO Abstract - Discussion of Phase III Study Findings on Momelotinib vs. Ruxolitinib in JAK Inhibitor - Naive Patients with Myelofibrosis 2017 Jun. Mesa RA. 2017 ASH Meeting on Hematologic Malignancies (MHM) 2017 May. Mesa RA. Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines 2017 Mar. Mesa RA. Highlights from ASCO 2016 for Myeloproliferative Neoplasm 2016 Jun. Mesa RA. State of the Art in Myeloproliferative Diseases 2016 Jun. Mesa RA. Updates on PERSIST-1 Trial of Pacritinib for Myelofibrosis 2016 Jun. Henry DH, Mesa RA, Spivak J, Silver RT, Verstovsek S. MPN Updates Your Source for Myeloproliferative Neoplasm News 2016 Apr. 17 p. Mesa RA. What's Next for MPN? 2016 Apr. Mesa RA. Individualizing Care for MPN Patients 2016 Apr. Mesa RA. How to Manage MPN Patients 2016 Apr. Mesa RA. Update in Polycythemia Vera 2016 Mar. Mesa RA. MPN Research Updates from a Panel of Experts. http://www.patientpower.info/video/ash-coverage-mpn-research-updates-from-a-panel-of-experts/?autoplay=1 2015 Dec. Mesa RA. Heme Themes: Challenges in averting the progression of MPN, MDS 2015 Sep. Mesa RA. Ruxolitinib significantly improved symptom burden for patients with hydroxyurea-resistant PV.). http://www.healio.com/hematology-oncology/education-lab/mpn-central/interactive/mc-ash-mesa 2015 Jul. Mesa RA. PERSIST-1 phase III study of pacritinib versus BAT in PMF, PPV-MF, or PET-MF. http://oncology.tv/OncologyTVNetwork/TabId/1455/VideoId/1271/PERSIST1-Phase-III-Study-Of-Pacritinib-Versus-BAT-In-PMF-PPVMF-Or-PETMF.aspx 2015 Jul. Mesa RA. Highlights from ASCO 2015: Results from Phase 3 PERSIST-1 clinical trial. Available at: http://www.healio.com/hematology-oncology/education-lab/mpn-central/interactive/video-interviews?bclid=4106077613001 2015 Jul. Mesa RA. Gender Issues and MPN. Available at: http://www.healio.com/hematology-oncology/education-lab/mpn-central/interactive/video-interviews?bclid=4106077613001 2015 Jul. Helwick, C (Cited Mesa RA, Egyed M's abstract for this article). Helwick C (author): Pacritinib for Myelofibrosis: Effective in Patients with Thrombocytopenia; Reference: Mesa RA, Egyed M, Szoke A, et al: Results of the PERSIST-1 phase III study of pacritinib versus best available therapy in primary myelofibrosis, pos 2015 Jul. Mesa RA. PERSIST-1 Trial. http://l39gg632kcb0ewpfj-sites-default-files.s3.amazonaws.com/ASCO_2015/OE_ASCO_29_Mesa.mp4 2015 Jun. Mesa RA. Ruben A. Mesa, MD, Summarizes Results of the PERSIST-1 Study on Myelofibrosis. http://video.ascopost.com/conferences/2015-asco-annual-meeting/results-of-the-persist-1-study-on-myelofibrosis/ 2015 Jun. Mesa RA. Results of the PERSIST-1 Study on Myelofibrosis. http://video.ascopost.com/conferences/2015-asco-annual-meeting/results-of-the-persist-1-study-on-myelofibrosis-1/ 2015 Jun. Geyer HL, Mesa RA. Disease burden for the patient with myelofibrosis: Goals and response with therapy London, UK: Future Science Group; 2015 May. 19 p. Mesa RA. Staging and Diagnosing. CancerCare Teleconference: Progress in the Treatment of Polycythemia Vera (PV) 2015 May. Mesa RA. Overview of Polycythemia Vera (PV). CancerCare Teleconference: Progress in the Treatment of Polycythemia Vera (PV) 2015 May. Mesa RA. Current Standard of Care. CancerCare Teleconference: Progress in the Treatment of Polycythemia Vera (PV) 2015 May. Mesa RA. ASCO 2015 Interview (Chicago). http://live.promenade.hu/congressreport/videos/asco2015/may30/interview/ASCO-2015-Interview-Ruben-A-Mesa_x264.mp4 2015 May. Mesa RA. Novel JAK inhibitor pacritinib proving effective for easing symptoms of myelofibrosis. http://ecancer.org/video/3721/novel-jak-inhibitor-pacritinib-proving-effective-for-easing-symptoms-of-myelofibrosis.php 2015 May. Mesa RA. Ask the Expert: Polycythemia Vera. http://news.cancerconnect.com/have-a-question-about-polycythemia-vera-ask-the-expert/ 2015 Apr. Mesa RA. The Efficacy and Safety of Continued Hydroxyurea Therapy Versus Switching to Ruxolitinib in Patients with Polycythemia Vera. http://oncology.tv/OncologyTVNetwork/TabId/1455/VideoId/977/The-Efficacy-And-Safety-Of-Continued-Hydroxyurea-Therapy-Versus-Switc 2014 Dec. Mesa RA. ASH 2014 Coverage: JAK Inhibitor Approved for the Treatment of Polycythemia Vera (PV). http://www.patientpower.info/video/ash-coverage-jak-inhibitor-approved-for-the-treatment-of-polycythemia-vera-pv 2014 Dec. Mesa RA. Conozca los alimentos cancerigenos. http://univisionarizona.univision.com/salud/videos-de-salud/video/2014-12-15/conozca-los-alimentos-cancerigenos 2014 Dec. Mesa RA. Treatment of MPNs. http://learningcenter.ehaweb.org/eha/2012/interview/91401/ruben.mesa.treatment.of.mpns.html 2014 Dec. Geyer H, Mesa R. MPN Symptoms and Quality of Life 2014 Nov. Mesa RA. Your Quality-of-Life Concerns 2014 Nov. Mesa RA. Your Quality-of-Life Concerns 2014 Nov. Mesa RA. Overview of MPN 2014 Nov. Mesa R, Kiladjian JJ, Harrison C, Verstovsek S, Vannucchi A. Myeloproliferative Neoplasms (edited) 2014 Nov. Mesa R. Myelofibrosis Current Therapy and Management 2014 Nov. Mesa RA. Atypical Infections While Being Treated with a JAK Inhibitor (panel discussion) 2014 Sep. Mesa RA. How Gene Mutations are Affecting Diagnosis and Therapeutic Approaches in MDS and MPNs. http://www.patientpower.info/video/how-gene-mutations-are-affecting-diagnostic-and-therapeutic-approaches-in-mds-and-mpns 2014 Sep. Mesa RA. Loss of Response While Being Treated with a JAK Inhibitor (panel discussion) 2014 Sep. Mesa RA. EHA Quick Take: ENESTND 5-Year Follow-up 2014 Jun. Mesa RA. The New Frontier in Polycythemia Vera: A Fresh Look at Diagnosis, Prognosis, and Treatment. www.peervoice.com/pvr150 2014 May. Mesa RA. How Do MPNs Develop? http://goo.gl/ODQwFh 2014 Mar. Mesa RA. Understanding Why Myeloproliferative Neoplasms Develop. http://www.patientpower.info/video/understanding-why-myeloproliferative-neoplasms-develop 2014 Mar. Mesa RA. Living Stronger and Longer with MPNs 2014 Feb. Mesa RA. The Fatigue Project: Improving Quality of Life for MPN Patients. http://www.patientpower.info/video/the-fatigue-project-improving-quality-of-life-for-mpn-patients 2014 Feb. Mesa RA. MPN Research: It Takes a Village to Make a Difference. http://www.patientpower.info/video/mpn-research-it-takes-a-village-to-make-a-difference 2014 Jan. Mesa RA. Understanding the Evolving MPN Treatment Landscape 2013 Dec. Mesa RA. Overview of Polycythemia, Staging and Diagnosing, Current Standard of Care. CancerCare Teleconference, Q 2013 Dec. Mesa RA. Tratamientos prometedores para la mielofibrosis, ahora y en camino. https://vimeo.com/patientpower/review/78461603/4c15f217b4 2013 Nov. Mesa RA. Mayo Clinic to Open Stem Cell Research Lab. Available at: http://cronkitenewsonline.com/2013/09/mayo-clinic-opens-stem-cell-research-lab/ 2013 Sep. Mesa RA. Myelofibrosis: Key Prognostic Factors 2013 Aug. Mesa RA. Interactive broadcast about MPN 2013 Aug. Mesa RA. Should New MPN Medicines Be Covered by Insurance and Government Programs? http://www.patientpower.info/video/should-new-mpn-medicines-be-covered-by-insurance-and-government-programs?autoplay=1 2013 Jul. Mesa RA. What the Latest Research Studies Mean for Myelofibrosis Patients. http://www.patientpower.info/video/what-the-latest-research-studies-mean-for-myelofibrosis-patients 2013 Jul. Mesa RA. MPN Advocacy Report of the 18th Congress of the European Hematology Association in Regards to Myeloproliferative Neoplasms. http://mpnadvocacy.com/2013/06/dr-ruben-mesa-report-from-the-european-hematology-association/ 2013 Jun. Mesa RA. Communicating with Your Health Care Team, including Your Pharmacist 2013 Apr. Mesa RA. The Important Role of Adherence in the Management of CML 2013 Apr. Mesa RA. Overview of Current Treatments for Chronic Myelogenous Leukemia (CML) 2013 Apr. Mesa RA. Overview of Current Treatments for Chronic Myelogenous Leukemia (CML) 2013 Apr. Mesa RA. New Treatment Approaches and Clinical Trials 2013 Apr. Mesa RA. Dr. Mesa on the Mechanism of Action of Ruxolitinib in CML. http://www.targetedhc.com/targeted-communications/Dr-Mesa-on-the-Mechanism-of-Action-of-Ruxolitinib-in-CML 2013 Mar.\n\nJournal Article\n\nPalmer J, Scherber R, Girardo M, Geyer H, Kosiorek H, Dueck A, Jain T, Mesa R. Patient Perspectives Regarding Allogeneic Bone Marrow Transplantation in Myelofibrosis Biol Blood Marrow Transplant 2019 Feb;25(2):398-402. Gupta V, Kosiorek HE, Mead A, Klisovic RB, Galvin JP, Berenzon D, Yacoub A, Viswabandya A, Mesa RA, Goldberg J, Price L, Salama ME, Weinberg RS, Rampal R, Farnoud N, Dueck AC, Mascarenhas JO, Hoffman R. Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study Biol Blood Marrow Transplant 2019 Feb;25(2):256-264. Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, Komrokji R, Arruda A, Najfeld V, Sandy L, Medina J, Litvin R, Famulare CA, Patel MA, Malloy M, Castro-Malaspina H, Giralt S, Weinberg RS, Mascarenhas JO, Mesa R, Rondelli D, Dueck AC, Levine RL, Gupta V, Hoffman R, Rampal RK. Impact of high molecular risk mutations on transplant outcomes in patients with myelofibrosis Biol Blood Marrow Transplant 2019 Jan;. Mazza GL, Kunze KL, Langlais BT, Kosiorek HE, DeWees TA, Geyer HL, Scherber RM, Mesa RA, Dueck AC. Item nonresponse on the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF): a comparison of missing data strategies Leuk Lymphoma 2019 Jan;. Yang M, Covington MF, Nguyen BD, Johnson GB, Mesa RA, Roarke MC. (99m)Tc-Sulfur Colloid Bone Marrow Scintigraphy in Diagnosis of Diffuse Pulmonary Extramedullary Hematopoiesis Secondary to Myelofibrosis J Nucl Med Technol 2018 Dec;46(4):368-372. Rampal RK, Mascarenhas JO, Kosiorek HE, Price L, Berenzon D, Hexner E, Abboud CN, Kremyanskaya M, Weinberg RS, Salama ME, Menghrajani K, Najfeld V, Sandy L, Heaney ML, Levine RL, Mesa RA, Dueck AC, Goldberg JD, Hoffman R. Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms Blood Adv 2018 Dec;2(24):3572-3580. Scherber RM, Mesa RA. Managing myelofibrosis (MF) that \"blasts\" through: Advancements in the treatment of relapsed/refractor y and blast-phase MF Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):118-126. Huberty J, Eckert R, Larkey L, Gowin K, Mitchell J, Mesa R. Perceptions of Myeloproliferative Neoplasm Patients Participating in an Online Yoga Intervention: A Qualitative Study Integr Cancer Ther 2018 Oct;17(4):1150-1162. Gupta V, Kosiorek HE, Mead A, Klisovic RB, Galvin JP, Berenzon D, Yacoub A, Viswabandya A, Mesa RA, Goldberg J, Price L, Salama ME, Weinberg RS, Rampal R, Farnoud N, Dueck AC, Mascarenhas JO, Hoffman R. Ruxolitinib Therapy Followed by Reduced Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis-Myeloproliferative Disorders Research Consortium 114 study. PMID: 30205231, doi: 10.1016/j.bbmt.2018.09.001. [Epub ahead of print] Biol Blood Marrow Transplant 2018 Sep;:30556-30561. Mesa RA. Refining the management of polycythemia vera Clin Adv Hematol Oncol 2018 Sep;16(9):587-589. Menghrajani K, Boonstra PS, Mercer JA, Perkins C, Gowin KL, Weber AA, Mesa R, Gotlib JR, Wang L, Singer JW, Talpaz M. Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis Leuk Lymphoma 2018 Sep;. Mesa R, Boccia RV, Grunwald MR, Oh ST, Colucci P, Paranagama D, Parasuraman S, Stein BL. Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States Clin Lymphoma Myeloma Leuk 2018 Sep;18(9):590-596. Mughal TI, Lion T, Abdel-Wahab O, Mesa R, Scherber RM, Perrotti D, Mauro M, Verstovsek S, Saglio G, Van Etten RA, Kralovics R. Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms. doi: 10.1002/hon.2537. [Epub ahead of print] Review. PMID:30074634 Hematol Oncol 2018 Aug;. Grunwald MR, Stein BL, Boccia RV, Oh ST, Paranagama D, Parasuraman S, Colucci P, Mesa R. Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States Clin Lymphoma Myeloma Leuk 2018 Aug;. Langlais BT, Geyer H, Scherber R, Mesa RA, Dueck AC. Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? PMID: 30033837 Leuk Lymphoma 2018 Jul;22:1-7. Padrnos L, Bennett R, Kosiorek H, Dueck AC, Northfelt D, Mikhael J, Tibes R, Khera N, Mesa RA. Living with Cancer: an"
    }
}